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 An urgent problem for pharmaceutical industry is that the water solubility of 
an estimated 40-70% of the newly developed active pharmaceutical ingredients (API) 
are so poor that they cannot be formulated on their own.  One interesting topic is to 
use molecular containers as the solubilizing agents.  Supramolecular chemistry has 
always been an interesting research area and during the past decades, various new 
supramolecular host•guest systems have been developed.  Cucurbit[n]urils (CB[n]) 
are very promising molecular containers as drug delivery vehicles due to their 
outstanding recognition properties.  In order to discover the most suitable CB[n]-type 
containers as solubilizing agents, acyclic CB[n]-type containers have been 
synthesized and their recognition and formulation properties have been studied.  In 
this thesis, three chapters have been included to investigate the possibility of using 
CB[n]-type containers as solubilizing agents for pharmaceutical agents. 
  
 Chapter 1 gives an introduction to supramolecular chemistry and formulation 
techniques using molecular containers.  A literature review on the synthesis, 
functionalization and applications of cucurbit[n]uril is given and the application of 
cyclodextrins and CB[n] containers in formulation techniques is discussed. 
 Chapter 2 describes a series of acyclic CB[n]-type molecular containers (II-2a 
– II-2h) with different solubilizing groups bearing different charges for evaluation as 
potential drug solubilizing agents.  The X-ray crystal structures of the negative, 
positive and neutral hosts (host II-2b, II-2f, and II-2h) are reported.  For neutral (II-
2h) and positively charged (II-2f) hosts, intramolecular H-bonds and ion-dipole 
interactions between the solubilizing arms and the ureidyl C=O portals are observed 
as well as intrahost π−π stacking interactions which results in a self-filling of the 
cavity.  1H NMR and UV/Vis spectroscopy are used to measure the Ka values of hosts 
II-2a, II-2h, and II-2f toward guests with different charge and significant decrease is 
noted in binding affinities of the neutral (II-2h) and positive (II-2f).  The pKa of 7H+ 
alone and in the presence of differently charged hosts II-2a, II-2h, and II-2f are 
measured and the II-2a induces the largest pKa shift.  The poor recognition properties 
of hosts II-2h and II-2f are reflected in their phase-solubility diagrams with insoluble 
drugs (tamoxifen, 17-α–ethynylestradiol, and indomethacin).  In all cases, the anionic 
host II-2a functions more efficiently as a solubilizing agent than either neutral II-2h, 
or cationic host II-2f. 
 In chapter 3, we compare the ability of III-1a – III-1e to solubilize insoluble 
drugs relative to HP-β-CD.  Phase solubility diagrams are created for mixtures of 
containers III-1a – III-1e and HP- β-CD with 19 drugs. We find that the solubilizing 
  
ability of the best container (III-1a – III-1e) is superior to HP-β-CD in all cases.  A 
notable achievement is the solubilization of the developmental anticancer agent PBS-
1086. The acyclic CB[n]-type containers display an affinity for the steroid ring 
system, aromatic moieties of insoluble drugs, and cationic ammonium groups.  
Compound III-1b is generally the most potent (Ka up to and exceeding 106 M-1) 
container whereas both III-1a and III-1b display excellent solubility enhancement 
toward a broad range of insoluble drugs.  The broad scope of insoluble drugs that can 
be formulated with III-1a and III-1b – in many cases where HP- β-CD fails 
completely – makes acyclic CB[n]-type containers particularly attractive alternatives 
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Chapter 1: Introduction to Acyclic CB[n]-type Molecular 
Containers 
 
1.1 Introduction  
Supramolecular macrocycles has been arousing increasing interest over the past decades.  
Supramolecular chemistry has been defined by Jean-Marie Lehn as the “chemistry of 
molecular assemblies and of the intermolecular bond”.  Usually, these interactions involve 
non-covalent bonds established between the interacting species, and the majority of these 
interactions can be categorized as host-guest type interactions.  In a host-guest type 
interaction, a host is usually a larger molecule with a certain kind of binding sites or cavity, 
and a guest is usually a smaller molecule, which can be encapsulated into the binding site or 
cavity of the host molecule and non-covalent bonds are formed when a host molecule and a 
guest molecule are combined together.  The chemical nature of different host-guest systems 
can vary greatly from each other and there are a wide variety of host molecules, including 
enzymes and synthetic molecular containers.  During the past decades, chemists have found 
large success in design, synthesis, characterizing and applications of different synthetic 
molecular containers, including crown ethers, cyclodextrin (CD), calixarene, and 
cucurbit(n)urils (CB[n]).  These molecular containers may differ greatly in their physical and 
chemical properties like solubility and reactivity.  But their recognition properties are the 
most interesting feature for this category of compounds.  For example, CDs prefer to bind 
with hydrophobic compounds and CB[n]-type containers have high affinity towards cations.  





encapsulation principle. CDs are the most widely used class of molecular containers.  
Applications of molecular containers include odor elimination, drug delivery, separation 
techniques, and catalysis.  CB[n]-type containers, as the new generation of molecular 
containers, are well known for their high affinity towards cationic guests, especially 
ammonium alkanes and are showing great potentials in applications in various fields.  
Nevertheless, CB[n]-type containers have some weakness to overcome before they can be 
used in wider applications. For example, most of CB[n] family members have limited 
aqueous solubility and they are difficult to functionalize.   
 
1.2 Molecular Containers  
Host-guest chemistry is often referred to as the confinement of the guest molecule inside the 
cavity of a supramolecular host molecule.  In such situations the host molecules are also often 
referred to as molecular containers. 
 
1.2.1 Examples of Molecular Containers 
Crown ethers were first discovered by Charles Pedersen in 1967.1  These cyclic polyethers 
were synthesized from aromatic viyinal diols.  This category of compounds assumes a ring 
conformation and can vary greatly in terms of the ring size, ranging from 9 to 60 atoms.  The 
presence of the oxygen atoms in the macrocycle ring provided the crown ethers with the 
ability to interact with different cations by ion-dipole interactions.  Crown ethers with 5 to 10 
oxygen atom are known to be able to form salt-polyether complex with a wide range of 





Hg+, Hg2+, La3+, Tl+, Ce3+, and Pb2+.  After the discovery of crown ethers, a lot of work has 
been done to discover new type of molecular containers with different host-guest chemistry.  
For example, chemists have discovered various new molecular containers including 
calixarenes, which are macrocycle oligomers based on hydroxyl alkylation products of 
phenol derivatives and aldehydes, cyclodextrins, which are macrocyclic oligomers of 
saccharides, and cucurbiturils (CB[n]s), which are macrocycle oligomers of glycolurils linked 
by methylene bridges.  Among them, CB[n]-type molecular containers are of special interest 
to us. 
 
1.2.2 Introduction to CB[n]-type Containers. 
The synthesis of CB[n]s was first reported in 1905 by Behrend.2  In his report, he described 
an insoluble polymer from the condensation reaction between glycoluril and formaldehyde in 
concentrated HCl.  Mock, in 1981, has discovered that the compound synthesized by Behrend 
75 years earlier was a macrocycle comprising six glycoluril units and linked with twelve 
methylene bridges.3  This compound was named as cucurbituril since the shape of the 
molecule looks like a pumpkin.   
 
Figure I-1. Synthesis and structure of CB[n]. 
 
Ever since the report of CB[6], new CB[n] family members including CB[5], CB[7], CB[8] 





















































derivatives have also been identified.  Inverted CB[6] has been reported in 20058, which is a 
CB[6] container with one glycoluril pointing inside the cavity.  Another CB[6] analogue, ns-
CB[6] (Figure I-2) was also reported recently.9  It is a host with one methylene bridge 
missing from the CB[6] structure.  It was obtained from the condensation reaction between 
glycoluril (1 eq.) and inadequate amount of paraformaldehyde (2 eq.).  Further 
functionalization can be achieved by reacting this host with o-phthaladehyde to close up the 
opening between the two neighbouring un-bridged urea nitrogens. 
 
Figure I-2. Structure of ns-CB[6]. 
 
Besides the analogues with only a single cavity, a dual-cavity, bis-ns-CB[10] (Figure I-3), 
was also reported10 to be able to encapsulate two guest molecules with one guest in each of 
its cavities.  By reacting bis-ns-CB[10] with paraformaldehyde and imidazolidone under acid 
conditions, the two open cavities can be clipped by the imidazolidone units.  With this 
clipping mechanism, a [3]rotaxane was synthesized based on the encapsulation of 1,6-
hexanediamine derivatives in bis-ns-CB[10] followed by clipping with imidazolidone.11 
 



























































































































































































The different CB[n] homologues contain different numbers of glycoluril unites and have 
different cavity sizes.  Due to the difference in the size of the cavities, different CB[n] 
containers also have different binding properties towards different guest molecules.   
 
1.2.3 Applications of CB[n]-type Containers. 
CB[n] type containers are well known to bind selectively with cationic gusts with high 
binding affinities, especially alkane diammoniums.  Based on their outstanding recognition 
properties, a lot of applications have been developed for CB[n]-type containers.  
 
Figure I-4. Chemcially controlled molecular machine. 
 
Molecular machines formed by self-assembly processes have aroused great interest and 
CB[n]s have shown great potential in this area.  By providing chemical, electrochemical, or 
photochemical stimuli, the binding affinity of CB[n]s towards different guests can be 
manipulated easily and the hostguest system can be switched between different binding 












For example, Mock developed a pH-dependent molecular switch in 1990.13  In his study, a 
pseudo-rotaxane system was formed with CB[6] and triamine I-1 (Figure I-4), and the switch 
was controlled by the protonation of the aniline moiety.  CB[6] tended to bind with 
hexanediammonium moiety when the pH is lower than the pKa of the anilinium group.  When 
the pH is higher than 6.7, the aniline nitrogen atom was deprotonated which decreased the 
affinity of CB[6] towards hexanediammonium moiety and CB[6] shifted to the 
butanediammonium moiety.  In this way, CB[6] is able to shuttle along the guest, triamine, 
by changing the pH value.   
 
 
Figure I-5. Supramolecular cross-linked networks based on CB[8] ternary complex. 
 
Besides using the stimuli-responsive CB[n] complex to make molecular machines, chemist 
can also use the recognition properties of CB[n] complexes to build up other complicated 
supramolecular architectures.  Due to relatively large cavity size, CB[8] is known to be able 







have utilized this recognition property of CB[8] to build self-assembled supramolecular 
polymers, networks, and vesicles.  For example, Scherman in 2010 has reported the 
supramolecular cross-linked network via CB[8] complexes (Figure I-5).19  In his report, two 
different polymers were prepared bearing different side-chains: viologen groups or 
naphthoxy groups.  These two polymers do not cross-link with each other in aqueous 
solutions.  However, since methylviologen and hydroxynaphthalene will form a strong three-
component complex with CB[8] through a two-steps process (methylviologen is the first 
guest, and hydroxynaphthalene is the second guest), the polymer scaffold will be cross-linked 
by the two different pendants upon the addition of CB[8] and a porous hydrogel was 
obtained.  This hydrogel showed thermal reversibility and subsequent facile modulation of 
microstructure upon futher addition of CB[8] and thermal treatment. 
 
Figure I-6. CB[7] can be used to regulate enzyme activity. 
 





always been an interesting topic, and CB[n] compounds are of great potential in this area.  
With a careful designed system, the features of CB[n] host-guest systems like high selectivity 
and low toxicity can be fully taken advantage of.  One good example is from the Isaacs’ 
group, where CB[7] was successfully used to regulate the catalytic activity of bovine 
carbonic anhydrase (BCA) (Figure I-6).20  In this study, a special inhibitor of BCA, 
compound I-2,  was synthesized.  Compound I-2 contains a benzenesulfonamide unit which 
binds to the Zn co-factor of BCA, and an adamantylammonium unit which is the preferred 
guest for CB[7] (Ka ≈ 10 12 M-1).  The addition of the compound I-2 turns off the catalytic 
activity of BCA due to the formation of a stable complex BAC I-2 (Ka = 2.7 × 10 7 M-1).  It 
was observed that the catalytically activity of BCA was then recovered after the addition of 
CB[7] as the result of the formation of a more stable complex CB[7] I-2 sequestering the 
inhibitor I-2 from BCA.   
 
1.2.4 Functionalization of CB[n] Containers 
Despite all the advantages and outstanding properties regular CB[n]-type containers still have 
their weaknesses, including limited solubility in water, rigid skeleton and challenge to modify 
internal or external molecular surface of the CB[n] molecules.  Over the past years, numerous 
analogues and derivatives of CB[n]-type containers prepared in order to overcome these 
weaknesses.  The goal of these research projects was to manipulate the shape and size of the 
binding cavities of CB[n] molecules to alter their binding properties or directly introducing 
different functional groups to the host molecule so that eventually the applications of CB[n]-





One of the pathway is to utilize the formation reaction of CB[n] molecules and use 
substituted glycoluril derivatives to derivatize CB[n] compounds.  The first example was 
reported in 1992 by Stoddart and co-workers.  They reported the first characterized CB[n] 
derivative with the synthesis of Me10CB[5] from dimethylglycoluril and formaldehyde under 
acidic conditions.21  
 
Another important way to functionalized CB[n] molecules was discovered by Kim in 2003 
(Figure I-7).  They reported the direct oxidation reactions using K2S2O8 to obtain derivatives 
of CB[5] – CB[8].22,23  From the reaction between CB[n] molecules and K2S2O8 in water, 
perhydroxylated compound (HO)2nCB[n] were obtained and could be subsequently 
derivatized.  For example, (HO)2nCB[n] can be alkylated by treatment with allyl bromide to 
yield CB[6] with 12 allylic groups on the surface ((CH2=CHCH2O)12CB[6]).   
 
Figure I-7. Oxidation of CB[5] – CB[8]. 
 
The oxidation reaction has become an important pathway for functionalization of CB[n]s and 
various applications of functionalized CB[n] containers has been developed based on this 
method.  By reacting the (CH2=CHCH2O)12CB[6] with pentanethiol through photochemical 
reactions, CB[6] containers were anchored onto a glass surface granting the glass surface the 
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through the same pathway and Kim and co-workers have anchored modified CB[7] onto gold 
surface.24  Then glucose oxidase (GOx) was used as a model protein and decorated with 
ferrocenemethylammonium ions. Through the non-covalent interactions between CB[7] and 
ferrocenemethylammonium ions, the protein was attached on the gold solid surface, and 




Figure I-8. Supramolecular velcro based on CB[7]- and Fc- modified surfaces. 
 
Recently, Kim and co-workers have attached mono allylated CB[7] to a thiol poly ethylene 
imine (PEI) functionalized silica surface (Figure I-8).25  The surface (PEISH-[Si], I-3) was 
obtained by reacting ethylene sulfide with PEI decorated silica surface (PEI-[Si]). It was then 
reacted with alkene-functionalized monoallyloxy-CB[7] to yield CB[7]-[Si] (I-4).  Similarly, 
aminomethylferrocene (Fc , I-6) decorated silica surface (FC-[Si], I-5) was also obtained.  Fc 


























FC-[Si] (I-5) and CB[7]-[Si] (I-4) ideal for under water adhesion applications.  Like 
commercial velcro, these two functionalized surfaces hook up with each other with great 
strength in aqueous environment (maximum lap shear strength of the supramolecular velcro 
was 1.12 MPa).  Moreover, the adhesion can be reversed when Fc was oxidized to Fc+, since 
the affinity of CB[7] towards Fc+ is much weaker.  
 
 
Figure I-9. Synthesis of glycoluril hexamer. 
 
In order to obtain mono-functionalized CB[n] containers, the Isaacs’ group has discovered 
the synthetic route to make glycoruil hexamer (I-8).26,27,28  As has been reported, in CB[n] 
forming reactions, glycoluril oligomers linked by methylene bridges will form first. Once the 
oligomer chain has grown to a certain length, for example, hexamers, the cyclization will 
happen to the give the corresponding cyclic CB[n].  Once the oligomer is cyclized, the 
reaction becomes irreversible.  In 2011, the isaacs group reported the template synthesis of 
glycoluril oligomers28, where p-xylenediammoiun salt was used as the template molecule.  
Due to the flexible nature of the oligomers before cyclization, the guest molecule can expand 
the cavity of the host, separating the two unbridged glycoluril units, and prevent the NH tips 
(Figure I-9, atoms shown in red) from cyclizing into CB[6].  This compound is a very 

































































Figure I-10. Synthesis of monofunctionalized CB[6]. 
 
With The new glycoluril hexamer building block available, Isaacs and co-workers have 
synthesized a series of monofunctionalized CB[6] derivatives using the condensation reaction 
between the free ureidyl nitrogens and o-phthaladehyde derivative I-9 (Figure I-10).27,29  This 
derivative have a very similar cavity with CB[6] but can be easily functionalized on the 
aromatic ring. CB[6] derivatives I-10 made through this synthetic route has been applied in 
various fields including fluorescent sensor27,30, where the aromatic ring is a naphthalene ring, 
and self-assemble daisy chain29, where R group in Figure I-9 is a hydroxy group and was then 
further transferred into a isopropylamine group.  
 
Figure I-11. Synthesis of monofunctionalized CB[7]. 
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building block for CB[7] derivatives, which is even more interesting due to the relatively 
larger cavity size and higher solubility compared with CB[6] derivatives.  Instead of 
condensing glycoluril hexamers with o-phthaladehyde derivatives, a functionalized glycoluril 
was used in the condensation reaction with glycoluril hexamers.31 Figure I-11 shows the 
example of monofunctionalized CB[7] with a chloride on the posterior.  The chloride was 




Figure I-12. Self-assembly of monofunctionalized CB[7]. 
 
In 2012, Isaacs and co-workers have reported the CB[7] derivative by attaching a primary 
amine moiety to the CB[7] host with click chemistry (Figure I-12).31  The attached alkyl 
amine moiety is a good binding site for CB[7] and the CB[7] derivative undergoes a self-







Figure I-13. Synthesis of an elongated CB[6].analogue. 
 
Thanks to all the methods mentioned above, the CB[n] family has been greatly expanded and 
more functional CB[n] type container derivatives have been discovered and applied in 
various fields.  In order to expand the CB[n] family to even a larger range with more 
desirable properties, like higher aqueous solubility, different cavity size, or more flexible 
backbones, researchers have synthesized more CB[n] analogues based on the understanding 
of the step-wise mechanism of CB[n] formation reactions.  Isaacs and co-workers have 
synthesized compound I-16 in high yield (Figure I-13) from the condensation reaction 
between compound I-14 and a building block glycoluril dimer I-15.32  It was discovered that 
in the formation reaction of CB[n]s, phthalhydrazides serve as nucleophilic glycoluril 
surrogates.  And based on this mechanism, compound I-14 and glycoluril dimer I-15 should 
be able to cyclize and give cyclic CB[n] analogues I-16.  As expected, a CB[6] analogues 
was obtained with electrochemically, UV/Vis and fluorescent active aromatic “walls”.  
Moreover, the introduction of the aromatic walls has elongated the shapes of the containers 
(5.9 × 11.2 × 6.9 Å when R is COOEt) compared with the original circular CB[n] container 





modified depending on the substituent R groups. 
 
Figure I-14. Synthesis of acyclic CB[n] congeners. 
 
Recently, a lot of attention has also been focused on the synthesis of acyclic CB[n]-type 
containers which turns out to be an ideal pathway for functionalization CB[n] molecules.  
Many years ago, the Isaacs group reported the synthesis of an acyclic CB[n] congener I-1933 
with alternating glycoluril and aromatic units from the SN2 reaction between functionalized 
glycoruil I-17 and aromatic wall I-18 (Figure I-14).  The congener would preorganize into an 
a,a,a,a-conformation amd binds to positive charged guests tightly although relatively weaker 
than cyclic CB[n] (Ka is 104 M-1 towards hexanediamine, compared to 106 M-1 for CB[6]).  
Sindelar also reported the discovery of glycoluril trimer I-23 and I-24 from the condensation 
reaction of glycoluril derivative I-20 with glycoluril bisether I-21 or tetrakis hydroxyl methyl 
glycoluril I-22 (Figure I-14).34  The products has retained some of the recognition properties 





1, and for methylviologen  Ka = 7.5 × 104 M-1).   
 
Figure I-15. Synthesis of highly soluble acyclic CB[n]-type container 
 
Another very important category of acyclic CB[n] analogues was discovered in 2010 by 
Isaacs’ group.35  In this study, a glycoluril tetramer building block I-26 was synthesized first 
through a step-wise synthetic route and was then reacted with two equivalents of  sulfonated 
hydroquinone derivative I-27 to yield acyclic CB[n] congener I-28 (Figure I-15) in high 
yield.  Similarly, by using a naphthalene derivative I-29 instead of I-27 as the aromatic wall, 
another acyclic container I-30 was obtained.  The two acyclic congeners possess excellent 
binding properties toward typical positive guests for cyclic CB[n]’s.  There are several 
reasons for this: 1) the acyclic host molecule contains four glycoluril units which can provide 





the host; 2) the container assumes a C-shape conformation due to the glycoluril tetramer 
backbone which creates a hydrophobic cavity for the binding of hydrophobic compounds; 3) 
introduction of aromatic side walls will boost the π−π interaction with species with aromatic 
systems.  More importantly, due the four sulfonate groups attached to the aromatic wall, the 
aqueous solubility of the hosts have been dramatically enhance (346 mM in water for I-16) 
compare with cyclic CB[n]s.  These two leading compounds (XX and XX) have been proven 
of profound importance in various applications, and one of their most successful applications 
is to be used as drug delivery vehicles. 
 
1.3. Drug delivery Using CB[n]-type Molecular Containers. 
One core issue in pharmaceutical industry is the formulation of active pharmaceutical 
ingredients (APIs).36,37  There have been increasing numbers of newly discovered drug 
candidates with promising therapeutic effects in recent years.  However, according to the 
Biopharmaceutics Classification System (BSC), about 40 – 70% of them belong to the Class 
II with low solubility but high intestinal permeability (Figure I-16).38  To revive those drug 

























Figure I-16. Biopharmaceutics Classification System (BSC) for active pharmaceutical 
ingredients (APIs) 
 
Various formulation methods are known and they can mainly be divided into two categories: 
1) increasing the rate of dissolution (kinetic solubility) and 2) increasing the solubility at 
equilibrium.  The first category includes methods based on kinetically stabilizing the API at a 
higher free energy form which dissolve faster and initially reaches a higher concentration 
compared with the lower free energy form of the API, but eventually, the API will be 
transformed in the most stable low free energy form, which is why APIs formulated with 
these methods have problems in storage.  Methods including preparation of nanocrystal or 
solid dipersions of the API fall into this category.39,40  The other way is to increase solubility 
at equilibrium which includes methods like preparation of highly soluble pro-drugs, 
formation of salts, encapsulation into soluble drug delivery vehicles.41-45  Among those 
different methods, using supramolecular containers as drug delivery vehicles is of special 
interest to us. 
 
1.3.1 Molecular Container Technology in Drug Delivery. 
A variety of water-soluble containers including calix[n]arenes, cyclodextrins, and 
cucurbit[n]urils (Figure I-17) are known to have the ability to encapsulate smaller molecules.  
Theoretically, they will be able to form water-soluble hostguest complexes with appropriate 






Figure I-17. Supramolecular containers as drug delivery vehicles.  
 
1.3.2 Cyclodextrins in Formulation Techniques 
Cyclodextrin was first discovered in 1891 by Villiers46, and it mainly comprises a family of 
three members and other derivatives.  These three major cyclodextrins are crystalline, 
homogeneous, non-hygroscopic substances, which are torus-like macro-rings built up from 
glucopyranose units.  The α-cyclodextrin comprises six glucopyranose units, β-CD comprises 
seven such units, and γ-CD comprises eight such units (Figure I-18).  The shape of 
cyclodextrin is also displayed in Figure I-17.  It has a hydrophobic cavity and hydrophilic 
portals and outer walls.47,48,49 
 
Cyclodextrins (CD) have been one of the most widely used supramolecular containers in drug 
delivery systems.  They have achieved generally regarded as safe status by FDA and have 
been applied as solubilizing agents for different drugs.  The recognition properties of 
cyclodextrins make them suitable for drug delivery systmes: cyclodextrins have relatively 





have fast kinetics for the association and dissociation process.45,50,51  These properties make 
cyclodextrins able to encapsulate a wide range of different guests, increase their solubility to 
the desired level and release them rapidly upon dilution. 
 
Figure I-18. Cyclodextrin family.  
 
Numerous experiments have been done to improve aqueous solubility of drug candidates 
using cyclodextrins as the solubilzing agent.  To evalutate the efficiency of solubility 
enhancement that can be achieved with a given container requires the creation of a phase-
solublity diagram.  It was first proposed by Higuchi and Connors52,53, and is a plot of the total 
concentration of the solubilized drug candidate versus the concentration of the solubilizing 








































































































(Figure I-19).  
 
Figure I-19. Phase diagram showing different solubility behaviors. 
 
Type A indicates a highly soluble complex is formed with cyclodextrin, and can be further 
divided in to Ap, AL, and AN type.  AL type plots correspond to 1:1 binding while Ap and An 
plots usually indicates different binding modes.  An plots are sometimes due to the limited 
solubility of the hostdrug complex or the self-association of the host.  The slope of the AL 
type plots or the slope of the linear region of Ap and An plots can be used to calculate the 
value of Ka using the equation I-1 shown below where S0 is the intrinsic solubility of the 
drug. 
      (I-1) 


































Figure I-20. Compounds for drug solubility enhancement with cyclodextrin derivatives. 
 
In order to better perform in the solubility enhancement, functionalized cyclodextrin 
derivatives have been made.  Among them, hydroxyalkylated β-CDs (I-31 and I-32), and 
sulfonated β-CDs (I-33 and I-34) have been proven to be of great importance.54  Compared to 
their parent β-CD, whose low intrinsic solubility has limited their effectiveness in solubility 
enhancement, these functionalized β-CDs poccess the AL-type diagram pattern with the guest 
solubility increasing linearly up to 10% (w/v) concentration of the hosts.  Müller and Brauns 





of substitutions were efficient in solubilizing several water-insoluble drug (Figure I-20) like 
hydrocortisone (D-1), diazepam (D-4), indomethacin (D-6), and digitoxin (D-10).55  The 
sulfonated β-CDs (I-33 and I-34) is another important solubilizing agent, where the sulfonate 
group is introduced to improve the intrinsic solubility.  However, it was discovered that an 
alkyl linker was needed to separate the charges on the sulfonate groups form the CD cavity, 
which explained why the sulfobutyl-β-CD (I-34) has better affinity that sulfopropyl-β-CD (I-
33).  Also, a variety of water-insoluble drugs including testosterone (D-2), progesterone (D-
3), pilocarpine (D-5), naproxen (D-7), cinnarizine (D-8), indomethcin, thiabendazole (D-9), 
miconazole (D-11), warfarin (D-12), and papaverin (D-13), have been successfully 
solubilized by sulfobutyl-β-CD (I-34) (Figure I-20).56,57,58 
 
Figure I-21. Cyclodextrin increases stability of drugs. 
 
Besides the increase of solubility, the encapsulation of the drug molecules into the 
cyclodextrin cavity can also increase the stability.59  Once the drug molecule is encapsulated, 
the cyclodextrins can act as a shield, at least partially, to protect the drug molecule form other 
reactive compounds or restrain the conformation the molecule.  Lots of hydrolysis, oxidation, 
isomerization and rearrangement can be prevented in this way. For example, doxorubicin 




















hydrolysis, cleavage of the 9-hydroxymethyl ketone moiety followed by A-ring 
aromatization, and photodecomposition.60,61  When forming a supramolecular complex with 
γ-cyclodextrin, the A-ring of the doxorubicin was shielded by the cyclodextrin cavity and 
greatly slow down the decomposition the drug molecule.  Also, the hydrolysis of Aspirin 
(acetylsalicyclic acid) under acid conditions can be slowed down by 4 – 6 time at the 
presence of β-cyclodextrin.  This can be explained by the fact that when forming a stable 
complex, benzene ring of the drug molecule stays inside the cyclodextrin cavity and the steric 
hindrance results in a decrease in the rate of hydrolysis.62 
 
1.3.2 CB[n]-type Containers in Formulation Techniques 
Considering the outstanding properties of cucurbit[n]urils, potential successes may be 
achieved in drug delivery systems.  CB[n]-type containers have been well known for their 
outstanding affinities, selectivity and stimuli responsiveness for positive charged guests, 
especially alkylammoniums (up to 1015 M-1), which makes CB[n]-type containers a suitable 
vehicles for those drug candidates with solubility problems.63-68  Lots of work has been done 
to explore the application of CB[n]-type containers as drug delivery vehicles.  Kim and co-
workers has reported the self-assembled hollow nanocapsules (diameter 190 nm) of CB[6] 
derivatives69 as delivery vehicles for drugs like doxorubicin.  The nanocapsule can also be 
decorated noncovalently with targeting ligands like folate groups to achieve targeting effects.   
 
CB[7] and its derivatives are more interesting in this area due to its relatively higher solublity 





and Isaacs-Briken team.70  Day’s group have done in vitro cytotoxicity study of CB[7] and 
CB[8] as well as in vivo oral and IV administration in mice.71  The biocompatibility of CB[7] 
and CB[5] was tested on HepG2 and HEK293 cells by Isaacs-Briken team.  There are several 
reports on the encapsulation of drug molecules with CB[7] to ether increase the solubility or 
protect the drug molecule.72-78  For example, Kim have reported the formation of CB[7] with 
an anticancer agent: oxaliplatin, and it was discovered that encapsulation can increase the 
stability of the drug.72 
 
Figure I-22. Structure of monofunctionalized biotin-CB[7] encapsulatiing oxaliplatin for 
targeted delivery. 
 
Besides simply encapsulating drug molecules and enhancing solubility or stability, more 
complicated goals can be achieved with functionalized CB[7] derivatives, liking targeting 
effects, which has been widely explored recently and may greatly enhance the therapeutic 
effects and reduce side effects.  The Isaacs-Briken group have proposed a 





drug molecules.79  This CB[7] derivative I-35 has retained the binding properties of CB[7] 
and is able to encapsulate a variety of different drug while the biotin moiety act as the 
targeting ligand.  It was proven with L1210 cells which have overexpressed the biotin 
receptors that this biotin-CB[7] does selectively delivery oxaliplatin into the targeted cells, 
which implies a potential reduction in cumulative oxaliplatin doses which could result in 
reduction incidence of peripheral neuropathy.  
 
Figure I-23. Solubility enhancement for water-insoluble host with acyclic CB[n]-type 
containers. 
 
Acyclic CB[n]-type containers are very interesting compounds and have great potentials in 
drug delivery applications.35,80  Due to the acyclic structure, these containers are less rigid 
compared with the cyclic CB[n] containers, and they are much easier to functionalize.  The 
previously mentioned acyclic CB[n]-type container motor1 (I-16) and motor2 (I-18) 
synthesized by Isaacs’ group have been used as general solubilizing agents for a variety of 
water-insoluble drugs35 (Figure I-23).  With excellent aqueous solubility (up to 346 mM in 





guest molecules. For example, Motor1 container (I-16) is able to enhance the solubility of 
paclitaxel by approximately 2750-fold, melphalan by 655-fold and tamoxifen by 23-fold.  
Motor2 container (I-18) bind to camptothcin very well and solubilizes it up to 580-fold at a 
1:1 concentration ratio.  The huge success of these two acyclic compounds has implied a 
bright future of using acyclic CB[n] containers as drug solubilizing agents.  It is possible and 
necessary to develop a broader family of acyclic CB[n] containers that can enhance the 






Chapter 2. Acyclic CB[n]-Type Molecular Containers: Effect of 
Solubilizing Group on their Function as Solubilizing Excipients 
 
2.1 Introduction. 
A major thrust in the area of supramolecular chemistry is the development of macrocyclic 
compounds that act as molecular containers.81,82  Accordingly, the synthesis and basic 
molecular recognition properties of numerous classes of macrocycles including 
cyclodextrins, calixarenes, cyclophanes, crown ethers, self-assembled systems, and most 
recently pillararenes have been extensively studied.45,81,84-89  Importantly, the properties of 
guest compounds bound within molecular containers are distinct from those of the same 
compounds free in solution.  For example, the lifetime of high energy molecules like 
cyclobutadiene can be greatly extended,90 the photophysical properties of encapsulated dyes 
can be improved,91 the conformation of natural and non-natural molecules can be 
controlled,87,92 the pKa of included guests can be shifted,93 and the reactions of certain 
substrates can be catalyzed.88,89  Over the past decade, the supramolecular chemistry of the 
cucurbit[n]uril family (Figure 1) of molecular containers12 has developed rapidly due in large 
part to the remarkable affinity and selectivity displayed by CB[n] toward their guests in 
water23,63,94 and the stimuli responsiveness of the resultant CB[n]•guest complexes.67  
Accordingly, CB[n] have been used as components of a large number of functional systems 
including molecular machines,67 sensing ensembles,95 supramolecular catalysts,96 
supramolecular polymers and materials,97 supramolecular velcro,25 membrane protein 






A major problem facing the pharmaceutical industry over the past 20 years has been the 
increase in the percentage of new chemical entities with excellent biological activity but such 
poor solubility characteristics that they cannot be formulated on their own.36,37  Accordingly, 
the pharmaceutical industry has developed numerous techniques to increase the solubility of 
these poorly soluble drugs including solid dispersions,39 the generation of nanocrystal solid 
forms,101 the preparation of amorphous solid forms of the API,102 the application of co-
solvents systems (e.g. EtOH / Cremophore), the formation of salts,43 higher solubility pro-
drugs,44 co-crystals,41 the encapsulation within or attachment to the outside of a dendrimer 
construct,42 and complexation within cyclodextrin molecular containers (e.g. HP-β-CD and 
CaptisolTM).50,103  Accordingly, researchers in the CB[n] area have begun to investigate the in 
vitro and in vivo toxicology of macrocyclic CB[n] containers,71,70,74 their ability to increase 
the solubility of insoluble drugs (e.g. camptothecin, albendazole, chlorambucil),73,75,76,77,104,105 
protect them against degradation,72,78 promote transformation into their biologically active 
form,106 and target them to specific cells.69,79   
 
Over the years, the Isaacs group has investigated the mechanism of CB[n] formation,26,27,107 
and used that mechanistic knowledge to prepare a variety of CB[n]-type receptors including 
CB[n] analogues,108 inverted CB[n],8 nor-seco-CB[n],9,10,109,110 and CB[n] 
derivatives.9,27,29,31,79  Most recently, we have synthesized acyclic CB[n]-type receptors 
comprising a central C-shaped glycoluril tetramer backbone, two terminal substituted 





groups.30,35,111,112  Previously we reported that II-2b is highly water soluble (346 mM), 
increases the solubility of insoluble drugs in water by factors of up to 2750-fold, is not toxic 
in in vitro and in vivo tests, and that the II-2b•paclitaxel complex efficiently kills HeLa 
cells.35 In complementary work we showed that related acyclic CB[n]-type receptors are 
capable of reversing the biological activity of the neuromuscular blocking agent rocuronium 
in rats.112  In this chapter we examine the influence of the nature of the solubilizing group 
(e.g. anionic, neutral, cationic) and the linker connecting the solubilizing group to the 
aromatic walls on the ability to act as a solubilizing agent. 
 
 
Figure II-1. Structures of molecular containers used previously as solubilizing agents for 






2.2 Results and Discussion.  
This results and discussion section is organized as follows.  First, we discuss the design and 
synthesis of a series of acyclic CB[n]-type receptors II-2a – II-2h and x-ray crystallographic 
determination of their solid state structures.  Subsequently, we show that these containers do 
not self-associate and study their container•guest recognition properties by 1H NMR and 
UV/Vis spectroscopy.  Finally, we describe the use of these compounds as containers for 
insoluble drugs as a function of charge of the solubilizing group employed. 
 
2.2.1 Design and Synthesis of Acyclic CB[n]-Type Receptors II-2a – II-2h. 
Previously, we have published the design and synthesis of compound II-2b and its use as a 
solubilizing excipient for insoluble pharmaceutical agents.35  Acyclic CB[n]-type receptor II-
2b is composed of a central glycoluril tetramer to which two aromatic walls have been 
attached.  The central glycoluril tetramer imparts an overall C-shape to compound II-2b 
which allows it to preferentially bind to and solubilize hydrophobic and cationic drugs 
whereas the aromatic walls were incorporated to allow II-2b to interact by π−π interactions 
with the wide variety of insoluble drugs which contain aromatic rings in their structures.  
Finally, container II-2b features four anionic sulfonate (SO3-) solubilizing groups which 
greatly enhance its solubility in water.35  In this paper, we prepare derivatives of II-2b – 
compounds II-2a – II-2h – that contain different solubilizing groups and study the influence 






Scheme II-1.  Synthesis of Acyclic CB[n] solubilizing excipients II-2a – II-2h.  Conditions: 
a) NaN3, DMSO, 90 °C, 95% yield,  b) PPh3, H2O, DMF, 50 °C, 39% yield, c) LiOH, then 
HCl, 67% yield. 
 
Synthetically, the preparation of compound II-2b involves the reaction of glycoluril tetramer 
II-3 with aromatic sidewall II-1b by a double electrophilic aromatic substitution reaction as 
described previously.35  Accordingly, to prepare derivatives of II-2b which differ in the 
nature of the solubilizing groups we needed to prepare a series of aromatic sidewalls.  In 
analogy to the preparation of II-1b, we allowed hydroquinone to react with butanesultone 
under basic conditions (aq. NaOH) to deliver II-1c in 80% yield.  To prepare aromatic 
sidewall II-1a with a shorter linker between the aromatic ring and the SO3- groups we first 
reacted commercially available diol II-1d with CBr4 and PPh3 to give II-1e in 91% yield 
according to the literature report.113  Next, II-1e was reacted with Na2SO3 in DMF to give 
aromatic sidewall II-1a in high yield (88%).  Reaction of glycoluril tetramer II-3 with the 
new anionic sidewalls II-1a and II-1c in trifluoroacetic acid (TFA) yielded acyclic CB[n]-
type receptors II-2a and II-2c in good yield (61 and 40%), respectively.  The series of hosts 
II-2a – II-2c differ only in the number of CH2-groups between the aromatic sidewall and the 






To prepare acyclic CB[n]-type receptor II-2f we first reacted glycoluril tetramer II-3 with II-
2e in hot TFA for 3 hours to obtain host tetra-bromo host II-2d in good yield (79%).  
Transformation of II-2d into the corresponding tetra-azido compound II-2e proceeded 
smoothly with NaN3 in DMSO.  Reduction of the tetra-azide host II-2e with PPh3 in 
DMF/H2O gave the corresponding tetra-amine host which was isolated in pure form as its 
tetrahydrochloride salt II-2f in 39% yield.  Lastly, we targeted the preparation of acyclic 
CB[n] type container II-2h which contains uncharged solubilizing arms.  For this purpose we 
reacted commercially available diol II-1d with glycoluril tetramer II-3 with in a mixed 
solvent of TFA and Ac2O (v/v = 1:1)114 which delivered tetraacetoxy compound II-2g in 90% 
yield.  Hydrolysis of II-2g with an aqueous solution of LiOH followed by acidification with 
HCl gives host II-2h in 67% yield. 
 
2.2.2 X-ray Crystal Structures of Hosts II-2b, II-2f, and II-2h that differ in 
the charge on their solubilizing groups. 
We were fortunate to obtain the crystal structures for host II-2b,35 II-2f and II-2h, which are 
the representatives of the negative, neutral and positive hosts (Figure II-2).  As we expected, 
all of the three structures assume a C-shaped conformation, which can be attributed to the 
polycyclic nature of the glycoluril tetramer backbone.  In the crystal structure of II-2b 
(Figure II-2a), the substituted o-xylylene tips interact with by CH•••π interactions whereas 
the O(CH2)3SO3- arms are extended away from the cavity; the cavity is filled by a solvating 





opposing quaternary (MeC) carbon atoms (10.92 and 11.44 Å) on the glycoluril tetramer 
backbone of II-2b.  In the crystal the individual molecules of II-2b form tapes along the c-
axis.  The formation of tapes is driven by π−π interactions between the o-xylylene rings of II-
2b; the mean separation between the planes of the aromatic rings amounts to 3.49 Å.  The 
tapes stack parallel to one another along the a-axis.  For the cationic host II-2f (Figure II-2b) 
the distance between the opposing quaternary (MeC) carbon atoms amounts to 10.50 Å and 
10.62 Å which is slightly smaller than that observed for II-2b.  We attribute this decreased 
dimension of II-2f relative to II-2b to the folding of one aromatic wall into the cavity of II-
2f.  This self-complexation is driven by the formation of N-H•••O=C H-bonds / ion-dipole 
interactions between the OCH2CH2NH3+ solubilizing arms and the carbonyl portal (N•••O 
distance = 2.790 Å; N-H•••O angle = 160˚).  In order for II-2f to act as a container for guests 
the self-complexation process would need to be reversed. The self-complexation also results 
in an out-of-plane twist which extends one OCH2CH2NH3 arm toward a neighboring 
molecule of II-2f in the crystal which reciprocates and forms a dimeric motif driven by N-
H•••O=C H-bonds / ion-dipole interactions (N•••O distance = 2.790 Å; N-H•••O angle = 
165˚).  The dimers pack in the ac-plane which stack along the b-axis separated by chloride 
counterions.  A similar self-complexation phenomenon was observed in the crystal structure 
of II-2h (Figure II-2c).  Once again, the folding of the o-xylylene ring of II-2h into the cavity 
results in a decreased distance between the opposing quaternary (MeC) carbon atoms which 
amounts to 10.88 Å and 11.00 Å.  In this case the self-complexation is driven by O-H•••O=C 
H-bonding interactions between on of the OCH2CH2OH arms and the carbonyl portal 





of II-2h appear as dimeric pairs driven by π−π interactions (mean interplanar separation = 
3.5 Å).  Quite interestingly, a second conformation of II-2h is also observed in the crystal 
(Figure II-2d).  In this second conformation, the size of the cavity is increased as evidenced 
by the larger distance between the opposing quaternary (MeC) carbon atoms (12.23 and 
13.70 Å) and the centroid – centroid distance between the two terminal aromatic rings (10.29 
Å).  This result is significant because it provides direct evidence for the highly flexible nature 
of methylene bridged glycoluril oligomers in general and acyclic CB[n]-type receptors in 
general which had previously been surmised based on their ability to solubilize drugs with a 
range of sizes and single walled carbon nanotubes.35,115  These expanded conformers of II-2h 
occur in dimeric pairs within the crystal; the ArOCH2CH2OH wall and arm of one molecule 
fills the cavity of its partner and vice versa.116  Overall, the x-ray crystal structures point to a 
high level of conformational flexibility of the acyclic CB[n]-type receptors and highlight the 






Figure II-2.  Cross-eyed stereoviews of the X-ray crystal structures of: a) II-2b, b) II-2f, and 
c&d) two different conformations of II-2h in the crystal.  Color code: C, gray; H, white; N, 
blue; O, red; H-bonds, red-yellow striped. 
2.2.3 Hosts II-2a, II-2f, and II-2h Do Not Undergo Self-Association. 
A prerequisite for the use of negative, neutral and positive hosts as solubilizing agents for 
insoluble drugs is that they do not undergo strong self-association in water which would 
compete with the formation of the host•drug complexes.  Previously, we have performed 1H 
NMR dilution experiments with negatively charged host II-2b and determined a self-
association constant Ks = 47 M-1 by fitting the change in observed chemical shift as a 
function of host concentration.35  The low value of Ks (47  M-1) ensures that the majority of 





Accordingly, we performed related 1H NMR dilution experiments117 with the newly prepared 
neutral (II-2h) and positively charged (II-2f) hosts.  We did not observe any significant 
change in chemical shift of Ha over the accessible concentration ranges (II-2h: 1.3 mM – 
0.05 mM; 2f: 10.5 mM – 0.05 mM).  These result establish that hosts II-2f and II-2h do not 
undergo significant self-association in the 20 mM sodium phosphate buffered D2O (pH 7.4) 
used in the drug solubilization experiments described below. 
	  
2.2.4 Binding Studies Between Acyclic CB[n]-Type Receptors and Guests 
II-4 – II-8. 
This section describes our investigation of the binding between hosts II-2a – II-2c, II-
2f, and II-2h toward guests II-4 – II-8 (Figure II-3) by a combination of 1H NMR 
spectroscopy and direct and competition UV/Vis spectroscopic titrations. 
 
Figure II-3.  Chemical structures of guests used in this study. 
 
1H NMR INVESTIGATIONS OF THE BINDING INTERACTIONS.  In this section we use 
1H NMR experiments to qualitatively and quantitatively study the geometrical features 





qualitative 1H NMR study of the difference in binding of guest II-6 toward hosts II-
2a, II-2f, and II-2h.  Figure II-4a – c shows the 1H NMR spectra recorded for II-6 (1.0 
mM), and equimolar mixtures of II-6 (1.0 mM) with hosts II-2a (1.0 mM), II-2h (1.0 
mM) and II-2f (1.0 mM).  Interestingly, for an equimolar mixture of host II-2f and 
guest II-6 we do not observe any changes in chemical shift for protons Hb, Hc and Hd 
on guest II-6 or protons Ha on host II-2f.  We surmise that the interaction between 
host II-2a and guest II-6 is simply too weak to be detected at the 1 mM concentrations 
used.  In contrast, however, we do observe significant upfield shifts of the protons Hb, 
Hc and Hd on guest II-6 in the presence of neutral host II-2h (Figure II-4c) and 
negative host II-2a (Figure II-4d).  The upfield nature of the changes in chemical shift 
is indicative of guest 6 binding within the cavity of II-2h and II-2a as observed 
previously for (acyclic) CB[n]-type receptors.35,112,118,119 The larger upfield shift 
observed for protons Hb, Hc and Hd within the mixture of negative host II-2a (Figure 
II-2d) and guest II-6 relative to  neutral host II-2h and guest II-6 (Figure II-4c) 
indicates that the negatively charged host II-2a binds the dicationic guest significantly 
stronger than the neutral host II-2h.  It was also observed that the resonances for 
protons Ha on the aromatic sidewalls of hosts II-2h and II-2a undergo a downfield 
shift upon complexation with guest II-6.  This observation can be explained by the 
fact that the neutral and positive hosts undergo π−π interactions between their 
aromatic walls within the uncomplexed host (Figure II-2) which shifts the resonances 
for protons Ha upfield (≈ 6.45 ppm).  Binding to guest II-6 breaks the π−π interactions 






Figure II-4.  1H NMR recorded (400 MHz, RT, 20 mM sodium phosphate buffered D2O, pH 
7.4) for: a) II-6, b) an equimolar mixture of II-2f (positive host) and II-6, (c) and equimolar 
mixture of II-2h (neutral host) and II-6, and (d) and equimolar mixture of II-2a (negative 
host) and II-6. 
 
After performing these initial 1H NMR experiments which showed substantial 
differences in the complexation behavior of negative, neutral, and positively charged 
hosts II-2a, II-2f, and II-2h toward diammonium ion II-6 we decided to determine the 
binding constants for these complexes by suitable titration experiments.  To measure 
the binding constant for complex II-2a• II-5c, we performed a direct 1H NMR titration 
experiment.  A solution containing a fixed concentration of host II-2a (0.5 mM) in 20 
mM sodium phosphate buffer (pH 7.4) was titrated with increasing concentrations of 
compound II-5c (Supporting Information).  We monitored the change in the 1H NMR 
chemical shift of proton Ha of host II-2a as a function of [II-5c] and fitted the data to a 
1:1 host:guest binding model which allowed us to determine the Ka value for II-2a• II-
5c (Ka = 3.33 × 103 M-1).  In an analogous manner, we performed direct 1H NMR 





between host II-2b and guests II-5b, II-5c, host II-2h and guests II-5b and II-5c, and 
host II-2f and guests II-5c and II-6 (Supporting Information). 
DIRECT UV/VIS TITRATIONS.  The 1H NMR titration experiments described above 
were not applicable for the determination of the Ka values for the tighter host guest 
complexes and complexes with poor solubility characteristics.  Accordingly, we 
decided to measure the Ka values for the remaining host-guest complexes by UV/Vis 
competition assays referenced to Ka values determined by direct UV/Vis titration.  
Dye II-4 was used in displacement assays to determine the Ka values of negative host 
II-2a towards different guests.  However, the application of II-4 in the detection of the 
Ka values of neutral host II-2h was limited by the fact that the dye induces 
precipitation of the host in the displacement experiments.  To avoid that problem, we 
chose dye II-8 as the indicator for competition experiments involving neutral host II-
2h.  Figure II-3a shows the UV/Vis spectra recorded when a fixed concentration of 
dye II-4 (10.0 µM) was titrated with negative host II-2a (0 – 0.45 mM).  We observed 
an isosbestic point at 533 nm which is indicative of the formation of a well defined II-
2a• II-4 complex.  Figure II-3b shows the best nonlinear least-squares fit of the 
absorbance at 550 nm versus concentration data to a 1:1 binding model which allowed 
us to determine the binding constant for complex II-2a• II-4 (Ka = (1.83 ± 0.08) × 105 
M-1).  Similar experiments were carried out to determine the binding constant 
constants for complex II-2h• II-8 (Ka = (1.32 ± 0.01) × 103 M-1, Supporting 
Information).  With those binding constants in hand we were able to perform the 







Figure II-5.  (a) UV/vis spectra obtained during the titration of a fixed concentration of II-4 
(10.0 µM) with II-2a (0 – 0.45 mM) and (b) plot of absorbance versus [II-2a] used to 
determine the Ka value of the II-2a• II-4 complex by nonlinear least-square fitting. 
 
UV/VIS COMPETITION ASSAYS.  To measure the values of Ka for guests whose 
binding affinity exceeds that measurable by direct 1H NMR titrations (approx. 104 M-
1) we turned to UV/Vis competition assays120 involving a colorimetric indicator as 
guest.  In these UV/Vis competition assays a complex between host and indicator (of 
known Ka) is initially formed – which shows a UV/Vis change upon host•indicator 
formation – and then titrated with an increasing concentration of UV/Vis silent guest.  
Upon competitive formation of the host•guest complex the indicator is released and 





[guest] to the competitive binding model (Supporting Information) as described 
previously112,118 then yields the unknown Ka value for host•guest.  For example, we 
performed a UV/Vis competition assay employing fixed concentrations of dye II-4 
(10.0 µM) and host II-2a (9.15 µM) and increasing concentrations of II-5a (0 – 65.0 
µM). The absorbance of dye II-4 was monitored and was then plotted against the 
concentration of guest II-5a.  Fitting the data to a competitive binding model, we 
determined the Ka value of II-2a• II-5a to be (1.68 ± 0.09) × 106 M-1.  Similar 
experiments were also performed for hosts II-2a, II-2b, II-2c and II-2h with guest II-
5a – II-5c, and II-6 (Table II-1, Supporting Information). 
 
Table II-1. Binding Constants (Ka, M-1) obtained for the interaction between host II-2a – II-
2f with various guests. 
 II-2a II-2b II-2c II-2h II-2f 
II-4 1.83 × 105 a 4.23 × 105 a 1.29 × 105 a ppt. n.d. 
II-5a 1.68 × 106 b 1.78 × 106 b 1.94 × 105 b 3.64 × 103 d – 
II-5b 4.47 × 104 b 1.67 × 105 d 5.54 × 104 b 2.36 × 103 d – 





II-6 4.59 × 106 b 4.37 × 106 b 1.12 × 106 b 1.13 × 104 c 327d 
II-8 n.d. n.d. n.d. 1.32 × 103 a n.d. 
aMeasured by direct titration monitored by UV/Vis absorption spectroscopy. bMeasured by 
competition with guest II-4 monitored by UV/Vis spectroscopy. cMeasured by competition 
with guest II-8 monitored by UV/Vis spectroscopy. dMeasured by direct titration monitored 
by 1H NMR. n.d.: not determined. –, below detection limit of 1H NMR titration.  ppt. = 
precipitate formed. 
 
TRENDS IN THE KA VALUES BETWEEN HOSTS II-2A, II-2H, AND II-2F AND GUESTS II-
5A – II-5C, AND II-6.  Hosts II-2a, II-2h, and II-2f differ in the nature of the charge on 
the solubilizing arms with a constant OCH2CH2 linker connecting them to the aromatic 
sidewall.  In previous work, we reported the x-ray crystal structure of host II-2b which 
showed that the sulfonate solubilizing groups extend away from the cavity and portals 
of the acyclic CB[n]-type receptor.35 However, the x-ray crystal structures of hosts II-
2h and II-2f reveal the presence of intramolecular H-bonds between the solubilizing 
arms and the ureidyl C=O portal of the host.  In addition, the presence of 
intramolecular H-bonds prompts the attached substituted o-xylylene sidewall to fold 
into the cavity to undergo offset π−π stacking.  Accordingly, for hosts II-2h and II-2f 
to undergo guest binding these intramolecular H-bonds, ion-dipole interactions, and 





relative to anionic host II-2a.  In accord with these expectations we note that 
adamantaneammonium ion II-5a binds 461-fold more tightly to anionic host II-2a 
than to neutral host II-2h; binding of II-5a to positively charged host II-2f was too 
weak to be detected.  Similarly, cyclohexanediammonium ion II-6 binds 406-fold 
more tightly to II-2a than it does to neutral host II-2h which in turn binds 35-fold 
more tightly to II-6 than cationic host II-2f does.  The effect of solubilizing group 
charge on the binding process toward neutral guests is somewhat different.  For a 
neutral guest like adamantanol II-5b the main driving force for complexation is the 
hydrophobic effect; the presence of a RO-H•••O=C H-bond is of no consequence to 
the binding because II-5b is H-bonded in both water and the complex. We find that 
host II-2a binds II-5b only 19-fold more tightly than II-2h which can be attributed to 
the loss of intrahost π−π interactions upon formation of the II-2h• II-5b complex.  
Host II-2f does not complex II-5b at all because it is energetically unfavorable to 
sacrifice intrahost ammonium•O=C ion-dipole interactions.  Interestingly, the 
influence of solubilizing group charge on the binding of negatively charged guests is 
different still.  For example, negatively charged host II-2a binds 30-fold more tightly 
to adamantane carboxylate II-5c than neutral host II-2h does again because of the loss 
of intrahost π−π interactions upon formation of the II-2h• II-5c complex.  However, 
host II-2f forms a relatively stable complex with II-5c (Ka = 645 M-1) which is 6-fold 
stronger than II-2h• II-5c.  We suggest that this increase in Ka is due to the presence 
of direct ammonium-carboxylate (H3N+•••-O2C) electrostatic interactions between the 





interactions are sufficiently strong to compensate for the loss or reduction of ion-
dipole interactions and π−π stacking interactions in uncomplexed host II-2f.  A related 
trend is noted in the recognition properties of anionic host II-2a toward cationic (II-
5a), neutral (II-5b), and negatively (II-5c) charged adamantane derivatives where II-
5a binds 38-fold more tightly than II-5b and 505-fold more tightly than II-5c.  
Overall, these results suggest that the charge on the solubilizing arms (e.g. anionic, 
neutral, cationic) has a major impact on the molecular recognition capabilities of the 
hosts.   
We also studied the length of the linker (O(CH2)nSO3-; n = 2, 3, 4) between the 
aromatic wall and the anionic solubilizing group.  For example, the binding affinities 
of II-2a, II-2b, and II-2c toward a common guest (e.g. II-5b) differ by only 4-fold 
from one another.  Because the magnitude of the differences in Ka for hosts II-2a, II-
2b, and II-2c toward a given guest are small we will not speculate further on the 
reasons for any observed differences. 
ACYCLIC CB[N]-TYPE RECEPTORS THAT DIFFER IN CHARGE INDUCE PKA SHIFTS OF 
BOUND GUESTS OF DIFFERENT MAGNITUDE.  It is well known in the literature that 
the pKa values for the guest within CB[n]-guest complexes can differ substantially 
from the pKa for guest alone; the magnitude of these complexation induced pKa shifts 
can exceed 4 pKa units.73,121  The origin of these pKa shifts can be traced to the strong 
ion-dipole interactions that occur between CB[n] host and cationic guests that are not 
possible with the corresponding neutral guests.  In this paper, we studied the influence 





when binding with acyclic CB[n] type receptors.  UV/Vis spectroscopy was used to 
monitor the protonation and deprotonation process of II-7.  Figure II-6 shows the plot 
of the percentage of the absorbance change of II-7 at 345 nm versus pH; the pKa value 
(Table II-2) was obtained by non-linear fitting of the data to the Equation II-1 
(Supporting Information).122,123  From Table II-2, we can observe an increase in pKa 
values in the presence of neutral host II-2h (pKa = 4.1) and negative host II-2a (pKa = 
4.9) compared with dye II-7 alone (pKa = 3.6), while a small decrease was observed in 
the presence of positive host II-2f (pKa = 3.4).  These changes in pKa are consistent 
with our expectations based on the net charge of the host.  For example, protonation of 
guest II-7 to give 7H+ is more favorable in the presence of neutral host II-2h because 
II-2h establishes ion-dipole interactions in the II-2h• II-7H+ that are not formed in the 
II-2h• II-7 complex.  Protonation of guest II-7 to give II-7H+ is even more favorable 
(larger pKa shift to 4.9) in the presence of anionic host II-2a not only because of ion-
dipole interactions in II-2a• II-7H+ complex but also because of the favorable ion-ion 
electrostatic interactions between the SO3- groups and II-7H+.  Finally, the pKa of the 
II-7H+ in the presence of cationic host II-2f is comparable to that of II-7H+ which 
probably reflects the weak binding between II-2f and II-7H+ due to binding of the 
OCH2CH2NH3+ arms of II-2f to its C=O portals and unfavorable ion-ion electrostatic 
interactions in the putative II-2f• II-7H+ complex. 
 












Figure II-6. Plot of absorbance change (%) versus pH to determine the pKa values of 6-
aminocoumarin  (35.6 µM) by itself (■), and with II-2f (cationic host, 1.5 mm, ▲), II-2h 
(neutral host, 1.2 mM, ●), and II-2a (anionic host, 1.5 mM, ▼). 
 
Table II-2. pKa values and binding constants (Ka) obtained for compound II-7 with host II-
2a, II-2h and II-2f. 
 II-7 II-2a• II-7 II-2h• II-7 II-2f• II-7 
pKa 3.6 4.9 4.1 3.4 
Ka (M-1)a n.a. 2.74 × 105 9.59 × 103 678 
n.a. = not applicable. – = no changes in 1H NMR chemical shift observed. a) Conditions: 20 
mM sodium phosphate buffer, pH 7.4, RT. 
 
Phase Solubility Diagrams for Acyclic CB[n] Type Receptors with Insoluble Drugs of 
Different Charges.  Our purpose in preparing and studying hosts II-2a, II-2h, and II-
2f was to determine whether the charge on the solubilizing arms of the acyclic CB[n]-





drugs.  Given that we observed significantly weaker binding of neutral (II-2h) and 
positively charged (II-2f) hosts toward most soluble guests as described above we 
anticipated that the anionic host II-2a would be the superior solubilizing agent for 
insoluble drugs.  Accordingly, we decided to test the ability of hosts II-2a, II-2h and 
II-2f to enhance the solubility of three insoluble drugs: tamoxifen, 17α–
ethynylestradiol, and indomethacin (Figure II-7).  We selected these three drugs 
because they differ in their net charge in neutral aqueous solution (tamoxifen, positive; 
17α–ethynylestradiol, neutral; indomethacin, negative).  For this purpose, we 
constructed phase solubility diagrams (plots of [drug] versus [host])117 for the each of 
the three hosts with each of the three water insoluble drugs (Figure II-8).  
Experimentally, a series of solutions containing known concentrations of host II-2a 
(or II-2h or II-2f) in sodium phosphate buffer (20 mM, pH 7.4) were stirred with 
excess of solid insoluble drug (e.g. tamoxifen, 17α–ethynylestradiol, or indomethacin) 
at RT until equilibrium was established.  The mixture was then filtered and the 
supernatant was collected.  A known concentration of benzene-1,3,5-tricarboxylic acid 
was added into the supernatant as an internal standard.  The concentration of the 
solubilized drug was then determined by 1H NMR spectroscopy using the integrals of 
the resonances of the known concentration of internal standard versus those of 
solubilized drug.  Figure II-8a-c shows the phase solubility diagrams constructed for 
tamoxifen, 17α–ethynylestradiol, and indomethacin with hosts II-2a, II-2h, and II-2f.  
As is readily apparent, negatively charged host II-2a is able to solubilize substantially 





be further rationalized based on an analysis of the phase solubility diagrams.117  For 
linear (AL) phase solubility diagrams, the initial slope of the PSD obeys equation 2 
where S0 is the intrinsic solubility of the drug, slope is the slope of the PSD, and Ka is 
the binding constant for the host•drug complex.117  In this manner, we calculated the 
binding constant for host II-2a towards all three drugs (1.83 × 103 M-1 for tamoxifen, 
1.73 × 104 M-1 for 17α - ethynylestradiol, and 6.07 × 103 M-1 for indomethacin).  It is 
also possible to use the phase solubility diagram to compare the behavior for a given 
drug (with common S0) with different hosts.  In this situation, the relative slopes of the 
phase solubility diagrams reflect the relative binding affinities of the different host-
drug complexes.  Accordingly, the inability of hosts II-2h and II-2f to solubilize any 
of the three drugs can be traced to their poor abilities as hosts (e.g. low Ka values).  In 
turn, this may be attributed to the blockade of the host cavity in II-2h and II-2f which 
was induced by intramolecular H-bonds, ion-dipole interactions, and π−π stacking. 
 



















Figure II-8.  Phase solubility diagrams constructed using solutions of hosts II-2a (■),II-2h 
(¡) and II-2f (▲) of known concentrations and an excess of solid drug: a) tamoxifen, b) 
17α-ethynylestradiol, and c) indomethacin. Conditions: 20 mM sodium phosphate buffered 
D2O (pH = 7.4, RT).  Solubility data were collected from single experiments. 
 








In summary, we have synthesized a series of acyclic CB[n]-type molecular containers (II-2a 
– II-2h) with different solubilizing groups bearing different charges for evaluation as 
potential drug solubilizing agents.  The X-ray crystal structures of the negative, positive and 
neutral hosts (host II-2b, II-2f, and II-2h) show us that all of these acyclic hosts assume a C-
shaped configuration.  However, for neutral (II-2h) and positively charged (II-2f) hosts, we 
observed intramolecular H-bonds and ion-dipole interactions between the solubilizing arms 
and the ureidyl C=O portals as well as intrahost π−π stacking interactions which result in a 
self-filling of the cavity.  We used 1H NMR and UV/Vis spectroscopy to measure the Ka 
values of hosts II-2a, II-2h, and II-2f toward guests with different charge and noted 
significant decrease in binding affinities of the neutral (II-2h) and positive (II-2f) hosts 
towards most guests.  There are exceptions, however, with adamantane carboxylate II-5c 
binding more tightly to positively changed host II-2f than to neutral host II-2h probably due 
to ion-ion electrostatic interactions.  We measured the pKa of 7H+ alone and in the presence 
of II-2a, II-2h, and II-2f and noted that the II-2a induces the largest pKa shift which we 
attribute to the presence of ion-ion electrostatic interactions in the II-2a• II-7H+ complex.  
Both the Ka and pKa measurements indicate that the solubilizing groups are not innocent 
bystanders.  The poor recognition properties of hosts II-2h and II-2f are reflected in their 
phase-solubility diagrams with insoluble drugs (tamoxifen, 17-α–ethynylestradiol, and 
indomethacin).  In all cases, the anionic host II-2a functions more efficiently as a solubilizing 
agent that either neutral II-2h, or cationic host II-2f. 





groups is far more efficient as a solubilizing agent than either II-2h or II-2f.  The work 
reinforces the need to employ solubilizing groups that do not impinge upon the innate 
recognition abilities of the host cavity by either self-association or self-folding due to H-
bonds, ion-dipole interaction, or π−π interactions.  Accordingly, further development of 
acyclic CB[n]-type receptors as solubilizing excipients for insoluble drugs will focus on 
derivatives with sulfonate solubilizing groups.  Because the synthesis of acyclic CB[n]-type 
receptors is modular, we are able to attach different aromatic sidewalls (e.g. naphthalene) to 
create tailor made analogues of II-2.  Ongoing work targets an understanding of the role of 
aromatic walls on the performance of analogues of II-2 as solubilizing excipients 
 
2.4 Experimental Section 
General Experimental.  Starting materials were purchased from commercial suppliers and 
were used without further purification or were prepared by literature procedures.  Compound 
II-1b, II-1e, II-2b and II-3 were prepared according to literature procedures.35,113,118  Melting 
points were measured on a Meltemp apparatus in open capillary tubes and are uncorrected. IR 
spectra were measured on a JASCO FT/IR 4100 spectrometer and are reported in cm-1. NMR 
spectra were measured at 400 MHz or 600 MHz for 1H and 125 MHz for 13C. Mass 
spectrometry was performed using a JEOL AccuTOF electrospray instrument using the 
electrospray ionization (ESI) technique. UV/Vis spectra were measured on a Varian Cary 100 
UV/Visible spectrophotometer.   
 





(0.18 g, 0.77 mmol) in TFA (2.0 mL).  The mixture was stirred and heated at 70 ˚C for 4 h. 
The solvent was removed with under reduced pressure and the solid was further dried under 
high vacuum.  The solid was washed with the mixture of water and acetone (1:2, v/v, 30 mL) 
twice and then dissolved in water and adjusted to pH = 7 by adding 1 M aqueous NaOH. The 
solvent was removed under reduced pressure and then the solid was further dried under high 
vacuum to yield II-2a as a white solid (0.21 g, 61%).  M.p. > 300 ˚C.  IR (ATR, cm-1): 
2990w, 1726s, 1480s, 1381m, 1318m, 1182, 1087s, 968m, 938m, 822m, 799s, 759m, 526m.  
1H NMR (400 MHz, D2O): 6.93 (s, 4H), 5.67 (d, J = 15.5, 2H), 5.56 (d, J = 16.0, 4H), 5.44 
(d, J = 7.6, 2H), 5.38 (d, J = 7.6, 2H), 5.35 (d, J = 16.3, 4H) 4.45 - 4.25 (m, 8H), 4.24 (d, J 
=16.0, 4H), 4.21 (d, J = 16.3, 4H) 4.10 (d, J = 15.5, 2H), 3.55 -3.40 (m, 4H), 3.35-3.20 (m, 
4H), 1.79 (s, 6H), 1.75 (s, 6H).  13C NMR (125 MHz, D2O, 1,4-dioxane as internal 
reference): δ 168.3, 167.8, 161.5, 139.5, 126.3, 90.3, 89.0, 82.8, 82.7, 77.4, 64.2, 62.0, 59.9, 
46.7, 27.5, 26.5.  High-Res MS (ESI): m/z 708.1271 ([M – 3Na + H]2-), calculated 708.1256. 
 
2.4 Support Information 
General Experimental. Starting materials were purchased from commercial suppliers and 
were used without further purification or were prepared by literature procedures.  Compound 
II-1b, II-1e, and II-2b were prepared according to literature procedures.35,118  Melting points 
were measured on a Meltemp apparatus in open capillary tubes and are uncorrected. IR 
spectra were measured on a JASCO FT/IR 4100 spectrometer and are reported in cm-1. NMR 
spectra were measured on Bruker DRX-400 instrument operating at 400 MHz for 1H and 125 





electrospray instrument (ESI). UV-Vis absorbance was measured on Varian Cary 100UV 
spectrophotometer. 
 
Synthetic Procedures and Characterization. The synthesis of II-1e and II-2b have been 
reported previously in literature.35,118 
 
Compound II-1a. Compound II-1e (2.00 g, 6.13 mmol) and Na2SO3 (3.10 
g, 24.5 mmol) was mixed and dissolved in H2O (20 mL). The mixture was 
stirred at 100 oC under N2 for 12 h.  The mixture was allowed to cool to 
RT and then acetone (40 mL) was added  The product precipitated as white crystals.  The 
solid was collected by filtration and then purified by recrystalization from water.  Drying 
under high vacuum gave II-1a as a white solid (2.01 g, 88%).  M.p. > 270 oC. IR (ATR, cm-
1): 3053w, 2994w, 2972w, 2882w, 1618w, 1512s, 1478m, 1265m, 1169s, 1038s, 817w, 
747m, 597m, 477m.  1H NMR (400 MHz, D2O): 6.98 (s, 4H), 4.35 (t, J = 6.2, 4H), 3.32 (t, J 
= 6.2, 4H).  13C NMR (125 MHz, D2O, 1,4-dioxane as internal reference): δ 151.5, 115.5, 
63.3, 49.3.  High-Res MS (ESI): m/z 162.0120 ([M – 2Na]2-), calculated for C10H12O8S22- 
161.9987. 
 
Compound II-1c. A solution of butanesultone (24.50 g, 200 
mmol) in 1,4-dioxane (160 mL) was added into a solution of 
hydroquinone (8.80 g, 80.0 mmol) in aqueous NaOH solution (10 





The solid was stirred with acetone (200 mL) then dried under high vacuum to yield II-1c as a 
white solid (25.112 g, 80%).  M.p. > 270 ˚C. IR (ATR, cm-1): 2961w, 2857w, 1622w, 1510s, 
1475w, 1237s, 1184s, 1049s, 822m, 604m, 534m, 479w.  1H NMR (400 MHz, D2O): 6.98 (s, 
4H), 4.05 (t, J = 5.7, 4H), 2.95 (t, J = 7.0, 4H), 1.80 - 2.00 (m, 8H).  13C NMR (125 MHz, 
D2O, 1, 4-dioxane as internal reference): δ 152.1, 115.8, 68.3, 50.1, 26.8, 20.3 (6 out of 6 
resonances were observed).  High-Res MS (ESI): m/z 381.0677 ([M – 2Na + H]-), calculated 
for C14H20O8S2H- 381.0678. 
 
Compound II-2a. Compound II-1a (0.28 g, 0.77 
mmol) was added into a solution of II-3 (0.181 g, 
0.23 mmol) in TFA (2.0 mL).  The mixture was 
stirred and heated at 70 ˚C for 4 h. The solvent was removed with under reduced pressure and 
the solid was further dried under high vacuum.  The solid was washed with the mixture of 
water and acetone (1:2, v/v, 30 mL) twice and then dissolved in water and adjusted to pH = 7 
by adding 1 M aqueous NaOH. The solvent was removed under reduced pressure and then 
the solid was further dried under high vacuum to yield II-2a as a white solid (0.208 g, 61%).  
M.p. > 300 oC.  IR (ATR, cm-1): 2990w, 1726s, 1480s, 1381m, 1318m, 1182, 1087s, 968m, 
938m, 822m, 799s, 759m, 526m.  1H NMR (400 MHz, D2O): 6.93 (s, 4H), 5.67 (d, J = 15.5, 
2H), 5.56 (d, J = 16.0, 4H), 5.44 (d, J = 7.6, 2H), 5.38 (d, J = 7.6, 2H), 5.35 (d, J = 16.3, 4H) 
4.45 - 4.25 (m, 8H), 4.24 (d, J =16.0, 4H), 4.21 (d, J = 16.3, 4H) 4.10 (d, J = 15.5, 2H), 3.55 -
3.40 (m, 4H), 3.35-3.20 (m, 4H), 1.79 (s, 6H), 1.75 (s, 6H).  13C NMR (125 MHz, D2O, 1,4-





77.4, 64.2, 62.0, 59.9, 46.7, 27.5, 26.5 (16 out of 16 resonances were observed).  High-Res 
MS (ESI): m/z 708.1271 ([M – 3Na + H]2-), calculated for C50H57N16O24S4Na2- 708.1256. 
 
Compound II-2c. Compound II-1c (6.50 g, 15.4 
mmol) was added into a solution of II-3 (3.000 
g, 3.84 mmol) in TFA (30 mL).  The mixture 
was stirred and heated at 70 oC for 4 h. The solvent was removed with under reduced 
pressure and the solid was further dried under high vacuum.  The solid was washed twice 
with the mixture of water and acetone (1:2, v/v, 300 mL) twice and then dissolved in water 
and adjusted to pH = 7 by adding 1 M aqueous NaOH. The solvent was removed under 
reduced pressure and then the solid was further dried under high vacuum to yield II-2c as a 
white solid (2.331 g, 40%).  m.p. > 300 oC.  IR (ATR, cm-1): 3936w, 1729s, 1474s, 1380m, 
1185s, 1088s, 1043s, 963m, 974m, 823m, 799s, 760m, 603m.  1H NMR (400 MHz, D2O): 
7.00 (s, 4H), 5.62 (d, J = 15.2, 2H), 5.51 (d, J = 16.0, 4H), 5.45(d, J = 8.9, 2H), 5.35 (d, J = 
8.9, 2H), 5.24 (d, J = 16.0, 4H), 4.30(d, J = 16.0, 4H), 4.25 (d, J = 16.0, 4H), 4.04 (d, J = 
15.2, 2H), 3.90 - 3.75(m, 8H), 2.90 - 2.75 (m, 4H), 2.70 - 2.55 (m, 4H), 1.72 (s, 12H), 1.80 - 
1.40 (m, 16H).  13C NMR (125 MHz, D2O, 1,4-dioxane as internal reference): δ 162.5, 162.3, 
156.8, 134.1, 122.4, 85.2, 83.8, 77.5, 76.8, 57.1, 54.6, 41.3, 34.2, 27.4, 22.1, 21.4 (16 out of 
18 resonances were observed).  High-Res MS (ESI): m/z 753.1977 ([M – 4Na + 2H]2+), 






Compound II-2d. Compound II-1e (1.70 g, 5.21 
mmol) and compound II-3 (1.20 g, 1.53 mmol) 
were mixed in a round bottom flask. TFA (12 
mL) was added, and the mixture was stirred at 70 °C for 3 h. The reaction mixture was 
poured into MeOH (100 mL), and the solid was collected with filtration. The crude product 
was stirred with water (150 mL) and then acetone (150 mL) at RT and the solid was isolated 
by filtration. Drying at high vacuum gave the product II-2d as a white powder (1.71 g, 79 %). 
M.p. 283 - 285 oC. IR (ATR, cm-1): 3000br, 1704m, 1456m, 1311m, 1225s, 1177s, 1080s, 
966m, 922m, 818m, 794s, 754m, 666m. 1H NMR (400 MHz, DMSO): 6.91 (s, 4H), 5.59 (d, J 
= 14.4, 2H), 5.51 (d, J = 15.2, 4H), 5.38 (d, J = 9.0, 2H), 5.30-5.25 (m, 6H), 4.50-4.40 (m, 
4H), 4.25-4.20 (m, 10H), 4.06 (d, J = 15.2, 4H), 3.90-3.80 (m, 8H), 1.69 (s, 6H), 1.66 (s, 6H).  
13C NMR (125 MHz, DMSO): δ 155.3, 154.0 150.3, 128.8, 116.0, 77.3, 76.2, 70.1, 70.8, 
70.7, 70.3, 52.9, 48.2, 34.5, 32.8, 16.6, 15.6, (16 out of 16 resonances were observed).  MS 
(ESI): m/z 765 ([M + p - xylenediamine + 2H]2+) 
 
Compound II-2g. Compound II-1d (1.021 g, 
5.12 mmol) and II-3 (1.000 g, 1.28 mmol) was 
mixed as solid and then dissolved in a mixture of 
TFA and Ac2O (1:1, 10 mL). The mixture was stirred at 70 oC for 3.5 h and then was poured 
into MeOH (150 mL). The solid was collected by filtration and was washed with acetone 
(100 mL) and water (100 mL). After drying under high vacuum, compound II-2g was 



















































1464s, 1377m, 1314m, 1228s, 1184s, 1083m, 974m, 822m, 797m. 1H NMR (400 MHz, 
DMSO): 6.84 (s, 4H), 5.58 (d, J = 16.3, 2H), 5.48 (d, J = 15.6, 4H), 5.37 (d, J = 9.0, 2H), 
5.27 (d, J = 9.0, 2H), 5.23 (d, J = 16.0, 4H), 4.45-4.30 (m, 4H), 4.30-4.05 (m, 16H), 3.50-
3.45 (m, 4H), 2.06 (s, 12H), 1.67 (s, 6H), 1.63 (s, 6H).  13C NMR (125 MHz, DMSO): δ 
170.4, 155.3, 153.9, 150.3, 128.4, 115.0, 77.3, 76.2, 71.8, 70.4, 68.6, 63.1, 53.1, 48.3, 34.4, 
20.7, 16.6, 15.6 (18 out of 18 resonances were observed).  MS (ESI): m/z 745 ([M + p - 
xylenediamine + 2H]2+). 
 
Compound II-2h. Compound II-2g (0.400 g, 
0.305 mmol) was added into an aqueous solution 
of LiOH (2.5 M, 7.5 mL). The mixture was 
stirred at 50  ºC for 0.5 h and then the solid was collected by filtration. The solid was wash 
with 0.1 M HCl to nertral and then stirred with EtOH (30 mL), and water (30 mL). After 
drying under high vacuum, a white solid was obtained (0.234 g, 67%).  M.p. > 300 oC.  IR 
(ATR, cm-1): 3428br, 2932w, 1728s, 1476s, 1379s, 1256s, 1184m, 1085m, 967m, 798m.  1H 
NMR (400 MHz, D2O): 6.95 (s, 4H), 5.62 (d, J = 15.3, 2H), 5.52 (d, J = 15.7, 4H), 5.43 (d, J 
= 8.0, 2H), 5.20 (d, J = 8.0, 2H), 4.72 (d, J = 16.2, 4H), 4.28 (d, J = 15.7, 4H), 4.23 (d, J = 
16.2, 4H), 4.19 (d, J = 15.3, 2H), 3.85-3.50 (m, 8H), 3.45-2.85 (m, 8H), 1.76 (s, 12H).  13C 
NMR (125 MHz, D2O, 1,4-dioxane as internal reference): δ 155.8, 149.8, 127.2, 114.7, 78.8, 
77.4, 71.0, 70.2, 60.0, 52.0, 47.8, 34.6, 15.7, 14.8 (16 out of 18 resonances were observed).  






























Compound II-2e. Compound II-2d (0.500 g, 
0.359 mmol) and NaN3 (0.281 g, 4.32 mmol) 
were mixed together and was then dissolved in 
DMSO (5.0 mL).  The mixed was stirred at 80 °C for 12 h and was then poured into H2O (50 
mL).  The solid was collected by filtration and was then washed with MeOH (50 mL).  After 
drying under vacuum, a white solid was obtained (0.423 g, 95%).  M.p. > 300 oC.  IR (ATR, 
cm-1):2932w, 2106m, 1730s, 1466s, 1378m, 1314m, 1230m, 1086m, 973w, 798m,   1H NMR 
(400 MHz, DMSO): 6.88 (s, 4H), 5.57 (d, J = 14.6, 2H), 5.47 (d, J = 15.1, 4H), 5.37 (d, J = 
8.7, 2H), 5.25 (d, J = 8.7, 2H), 5.24 (d, J = 16.1, 4H), 4.25 – 4.20 (m, 4H), 4.14 (d, J = 16.1, 
4H), 4.15 – 4.05 (m, 4H), 4.05 (d, J = 14.6, 4H), 4.03 (d, J = 15.1, 2H), 3.85-3.75 (m, 4H), 
3.55-3.45 (m, 4H), 1.69 (s, 6H), 1.66 (s, 6H).  13C NMR (125 MHz, DMSO,): δ 155.1, 153.8, 
150.2, 128.3, 115.0, 77.1, 76.0, 70.6, 70.2, 69.6, 52.8, 50.4, 34.2, 16.5, 15.4 (16 out of 16 
resonances were observed).  High-Res MS (ESI): m/z 689.3025 ([M + p - xylenediamine + 
2H]2+), calculated for C58H70N30O122+ 689.2894. 
 
Compound II-2f. Compound II-2e (0.031 g, 
0.0242 mmol) was mixed with 
triphenylphosphine (0.051 g, 0.193 mmol) and 
was then dissolved in the mixed solvent of DMSO (4 mL) and H2O (1 mL).  The mixture was 
stirred at 80 °C for 6 h and pH was adjusted to 1 with 6M HCl.  The resulting solution was 




























then crystallized with a mix solvent of H2O (0.5 mL) and acetone (1.5 mL).  The solid was 
then collected by centrifuge and after drying under vacuum, a white solid was obtained 
(0.012 g, 39%).  M.p. > 300 oC. IR (ATR, cm-1): 3435br, 3045m, 1726s, 1479s, 1379w, 
1318s, 1257s, 1231s, 1180s, 1093s.  1H NMR (400 MHz, D2O): 6.44 (s, 4H), 5.58 (d, J = 
15.3, 2H), 5.52 (d, J = 15.8, 4H), 5.46 (d, J = 9.2, 2H), 5.28 (d, J = 9.2, 2H), 5.27 (d, J = 
16.5, 4H), 4.31 (d, J = 15.8, 4H), 4.29 (d, J = 16.5, 4H), 4.13 (d, J = 15.3, 2H), 3.85 - 3.75 
(m, 4H), 3.65-3.55 (m, 4H), 3.350-3.10 (m, 8H), 1.78 (s, 6H), 1.77 (s, 6H).  13C NMR (125 
MHz, D2O, 1,4-dioxane as internal reference): δ 155.9, 155.7, 148.2, 126.8, 112.1, 78.6, 77.5, 
70.1, 70.0, 64.0, 51.5, 47.8, 38.4, 34.5, 17.0, 15.5, (16 out of 16 resonances were observed).  
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Figure S II-2. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 














Figure S II-4. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 














Figure S II-6. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 














Figure S II-8. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 









































Figure S II-13. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 














Figure S II-15. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 














Figure S II-17. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 





Procedure to measure the solubility of drugs with Host II-2a, II-2h and II-2f. Excess 
amount of drug was added into a solution of host II-2a/ II-2f/ II-2h of known concentration 
in deuterated sodium phosphate buffer (20 mM, pD = 7.4).  The suspended mixture was 
magnetically stirred at room temperature for 6 h. During this period, the pD value of the 
solution was monitored and adjusted back to 7.4 if it changed.  The mixture was then 
centrifuged twice (4200 rpm, 10 min). The 1H NMR spectrum of the supernatant was 
measured (400 MHz) with 1,3,5-benzenetricarboxylic acid (1.03 mM) as internal standard. 
The signal for the reference shows up at 8.35 ppm (s, 3H). Diagnostic signals for the 
dissolved drug were also integrated. From the ratio of integrations of reference peak relative 
to the drug peak, and the concentration of reference, the concentration of the drug can be 
calculated.  




















Figure S II-18. Phase diagram of mixtures of indomethacin and host II-2a, II-2f and II-2h, 






















[Host] (mM)  
Figure S II-19. Phase diagram of mixtures of 17α-ethynylestradiol and host II-2a, II-2f and 
II-2h, in 20 mM sodium phosphate buffer (pH = 7.4).  
 


















Figure S II-20. Phase diagram of mixtures of tamoxifen and host II-2a, II-2f and II-2h, in 







Figure S II-21. 1H NMR recorded for pharmaceutical agent indomethacin with II-2a (16 








Figure S II-22. 1H NMR recorded for pharmaceutical agent 17α-ethynylestradiol with II-2a 








Figure S II-23 1H NMR recorded for pharmaceutical agent tamoxifen with II-2a (14 mM) 






Determination of Ka Between Host II-2a – II-2h and Various Compounds.  In this work, 
1H NMR and UV/Vis spectroscopic methods were used in order to determine the Ka values 
for various host•guest complexes.  1H NMR spectroscopic method can measure Ka values up 
to 104 M-1 but for measurements of higher binding constants we need to use UV/Vis titration.  
The Ka value of hosts II-2a – II-2c with dye II-4 was obtained from direct UV/Vis titrations 
of fixed concentration of the dye by fitting the change of absorbance versus the concentration 
of host to a 1:1 binding model. Then dye II-4 was used as an indicator in the displacement 
assays to measure the binding constants of host II-2a – II-2c towards guest II-5a, II-5b and 
guest II-6 by fitting the change of absorbance versus the concentration of guest to a 
competitive binding model.  Similarly, the binding constant between host II-2h and dye II-8 
was determined by direct UV/Vis titration and Ka values between host II-2h and guest II-6 
was determined by indicator displacement assays with dye II-8 as the indicator.  Binding 
constants of II-2a, II-2h and II-2f toward guest II-5c , II-2b toward II-5b, and II-2h toward 
II-5a and II-5b are determined by direct 1H NMR titration and the chemical shift change 
versus the change of concentration was fitted to a 1:1 binding model to give Ka values.  The 
binding constant between II-2f and II-5c was also determined by 1H NMR methods.  The 
host•guest complex has a slow exchange on 1H NMR, and the concentrations of free host, 
free guest, binding host, binding guest can be determined by the ratio of the integrals of their 
own NMR signals.  The concentration was then used to calculate the binding constant of II-













Binding Models Used to Determine Values of Ka with Micromath Scientist 
1:1 Binding Model (NMR). 
// Micromath Scientist Model File 
// 1:1 Host:Guest binding model for NMR 
//This model assumes the guest concentration is fixed and host concentration is varied 
IndVars: ConcHostTot 
DepVars: Deltaobs 
Params: Ka, ConcGuestTot, Deltasat, Deltazero 
Ka = ConcHostGuest/(ConcHostFree*ConcGuestFree) 
ConcHostTot=ConcHostFree + ConcHostGuest 
ConcGuestTot=ConcGuestFree + ConcHostGuest 
Deltaobs = Deltazero + (Deltasat - Deltazero) * (ConcHostGuest/ConcGuestTot) 
//Constraints 
0 < ConcHostFree < ConcHostTot 
0 < Ka 
0 < ConcGuestFree < ConcGuestTot 
0 < ConcHostGuest < ConcHostTot 
 
1:1 Binding Model (UV/Vis). 
// Micromath Scientist Model File 
// 1:1 Host:Guest binding model 







Params: Ka, ConcGuestTot, SpectroscopicSignalMin, SpectroscopicSignalMax 
Ka = ConcHostGuest/(ConcHostFree*ConcGuestFree) 
ConcHostTot=ConcHostFree + ConcHostGuest 
ConcGuestTot=ConcGuestFree + ConcHostGuest 
SpectroscopicSignal = SpectroscopicSignalMin + (SpectroscopicSignalMax - 
SpectroscopicSignalMin) * (ConcHostGuest/ConcGuestTot) 
//Constraints 
0 < ConcHostFree < ConcHostTot 
0 < Ka 
0 < ConcGuestFree < ConcGuestTot 
0 < ConcHostGuest < ConcHostTot 
 
Competitive Binding (Indicator Displacement) Model. 
// MicroMath Scientist Model File 
IndVars: ConcAntot 
DepVars: Absorb 
Params: ConcHtot, ConcGtot, Khg, Kha, AbsorbMax, AbsorbMin 
Khg = ConcHG / (ConcH * ConcG) 
Kha = ConcHAn / (ConcH * ConcAn) 





ConcHtot = ConcH + ConcHG + ConcHAn 
ConcGtot = ConcHG + ConcG 
ConcAntot = ConcAn + ConcHAn 
0 < ConcHG < ConcHtot 
0 < ConcH < ConcHtot 
0 < ConcG < ConcGtot 










Figure S II-24. (A) UV/Vis spectra from the titration of dye 4 (10.0 µM) with II-2a (0 – 480 
µM) in 20 mM NaH2PO4 buffer (pH 7.4); (B) plot of the ΔA550 as a function of II-2a 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 binding 








Figure S II-25. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2a 
(9.15 µM) solution with II-5a (0 – 65 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 550 nm versus concentration for the displacement titration of II-









Figure S II-26. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2a 
(9.15 µM) solution with II-5b (0 – 480 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-
linear fitting plot of absorbance 550 nm versus concentration for the displacement titration of 









Figure S II-27. (A) 1H NMR spectra (400 MHz, 20 mM sodium phosphate buffer, pD = 7.4) 
recorded for a solution of II-2a (181 µM) and II-5c of variable concentrations (0 – 3.1 mM). 
(B) Plot of the chemical shift of the aromatic proton of II-2a as a function of II-5c 
concentration. The solid line represents the best non-linear fitting of the data to a 1:1 binding 








Figure S II-28. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2a 
(9.15 µM) solution with II-6 (0 – 32 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 550 nm versus concentration for the displacement titration of II-










Figure S II-29. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2a 
(9.15 µM) solution with 7 (0 – 32 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 550 nm versus concentration for the displacement titration of II-










Figure S II-30. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2b 
(9.18 µM) solution with II-5a (0 – 32 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 550 nm versus concentration for the displacement titration of II-









Figure S II-31. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2b 
(9.15 µM) solution with II-5b (0 – 32 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 550 nm versus concentration for the displacement titration of II-










Figure S II-32. (A) 1H NMR spectra (400 MHz, 20 mM sodium phosphate buffer, pD = 7.4) 
recorded for a solution of II-2b (2.0 mM) and II-5c of variable concentrations (0 – 8.0 mM). 
(B) Plot of the chemical shift of the aromatic proton of II-2b as a function of II-5c 
concentration. The solid line represents the best non-linear fitting of the data to a 1:1 binding 










Figure S II-33. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2b 
(9.18 µM) solution with II-6 (0 – 270 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 550 nm versus concentration for the displacement titration of II-








Figure S II-34. (A) UV/Vis spectra from the titration of dye II-4 (10.0 µM) with II-2c (0 – 
400 µM) in 20 mM NaH2PO4 buffer (pH 7.4); (B) plot of the ΔA550 as a function of II-2c 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 binding 









Figure S II-35. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2c 
(9.19 µM) solution with II-6 (0 – 74 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 550 nm versus concentration for the displacement titration of 6 







Figure S II-36. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2c 
(9.19 µM) solution with II-5a (0 – 130 µM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-
linear fitting plot of absorbance at 550 nm versus concentration for the displacement titration 










Figure S II-37. (A) Displacement titration of a solution of dye II-4 (10.0 µM) and host II-2c 
(9.19 µM) solution with II-5b (0 – 2.6 mM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-
linear fitting plot of absorbance at 550 nm versus concentration for the displacement titration 









Figure S II-38. (A) 1H NMR spectra (400 MHz, 20 mM sodium phosphate buffer, pD = 7.4) 
recorded for a solution of II-2c (1.055 mM) and II-5c of variable concentrations (0 – 16 
mM). (B) Plot of the chemical shift of the aromatic proton of II-2c as a function of II-5c 
concentration. The solid line represents the best non-linear fitting of the data to a 1:1 binding 








Figure S II-39. (A) UV/Vis spectra from the titration of dye II-8 (11.0 µM) with II-2h (0 – 
500 µM) in 20 mM NaH2PO4 buffer (pH 7.4); (B) plot of the ΔA550 as a function of II-2h 
concentration. The solid line represents the best non-linear fit of the data to a 1:1 binding 









Figure S II-40. (A) 1H NMR spectra (400 MHz, 20 mM sodium phosphate buffer, pD = 7.4) 
recorded for a solution of II-2h (0.350 mM) and II-5a of variable concentrations (0 – 5.0 
mM). (B) Plot of the chemical shift of the aromatic proton of II-2h as a function of II-5a 
concentration. The solid line represents the best non-linear fitting of the data to a 1:1 binding 








Figure S II-41. (A) 1H NMR spectra (400 MHz, 20 mM sodium phosphate buffer, pD = 7.4) 
recorded for a solution of II-2h (0.350 mM) and II-5b of variable concentrations (0 – 5.0 
mM). (B) Plot of the chemical shift of the aromatic proton of II-2h as a function of II-5b 
concentration. The solid line represents the best non-linear fitting of the data to a 1:1 binding 









Figure S II-42. (A) 1H NMR spectra (400 MHz, 20 mM sodium phosphate buffer, pD = 7.4) 
recorded for a solution of II-2h (0.350 mM) and II-5c of variable concentrations (0 – 11 
mM). (B) Plot of the chemical shift of the aromatic proton of II-2h as a function of II-5c 
concentration. The solid line represents the best non-linear fitting of the data to a 1:1 binding 








Figure S II-43. (A) Displacement titration of a solution of dye II-8 (11.0 µM) and host II-2h 
(385 µM) solution with II-6 (0 – 2.6 mM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 510 nm versus concentration for the displacement titration of II-








Figure S II-44. (A) Displacement titration of a solution of dye II-8 (76.5 µM) and host II-2h 
(83.2 µM) solution with II-7 (0 – 1.2 mM) (20 mM NaH2PO4 buffer, pH 7.4). (B) Non-linear 
fitting plot of absorbance at 550 nm versus concentration for the displacement titration of II-








Figure S II-45. (A) 1H NMR spectra (400 MHz, 20 mM sodium phosphate buffer, pD = 7.4) 
recorded for a solution of II-2f (1.055 mM) and II-6 of variable concentrations (0 – 22 mM). 
(B) Plot of the chemical shift of the aromatic proton of II-2f as a function of II-6 
concentration. The solid line represents the best non-linear fitting of the data to a 1:1 binding 








Figure S II-46. (A) 1H NMR spectra (400 MHz, 20 mM sodium phosphate buffer, pD = 7.4) 
recorded for a solution of II-2f (1.055 mM) and 7 of variable concentrations (0 – 11 mM). 
(B) Plot of the chemical shift of the aromatic proton of II-2f as a function of II-7 
concentration. The solid line represents the best non-linear fitting of the data to a 1:1 binding 







Figure S II-47.  1H NMR spectra recorded (D2O, 400 MHz, RT) for: a) II-5c (0.5 mM), b) 
II-2f (0.5 mM), c) a mixture of II-2f (0.5 mM) and II-5c (4.0 mM), and d) a mixture of II-2f 







Determination of pKa shift of guest II-7 when forming complexes with II-2a, II-2f and 
II-2h   UV/Vis spectroscopy was used in this work to determine the pKa values.  The direct 
pH titration of fixed concentrations of UV/Vis dye 7 and different hosts allowed us to 
determine their values of pKa by fitting to a pKa model.   
 
pKa Models Used to Determine Values of Ka with Micromath Scientist 
 
// Micromath Scientist Model File 
IndVars: pH 
DepVars: Iobs 


















Figure S II-48. (A) pH titration of a solution of dye II-7 (36.5 µM) solution (B) Non-linear 
fitting plot of absorbance versus pH for the pH titration of II-7 with using a model 










Figure S II-49. (A) pH titration of a solution of dye II-7 (36.5 µM) solution with II-2a (1.5 
mM) (B) Non-linear fitting plot of absorbance versus pH for the pH titration of II-7 with 










Figure S II-50. (A) pH titration of a solution of dye II-7 (36.5 µM) solution with II-2h (1.5 
mM) (B) Non-linear fitting plot of absorbance versus pH for the pH titration of II-7 with 







Figure S II-51. (A) pH titration of a solution of dye II-7 (36.5 µM) solution with II-2f (1.5 
mM) (B) Non-linear fitting plot of absorbance versus pH for the pH titration of II-7 using a 






Details of the X-ray crystallographic structure of II-2h.  A colorless prism-like specimen 
of C100H155N32O49.50, approximate dimensions 0.21 mm × 0.30 mm × 0.42 mm, was used for 
the X-ray crystallographic analysis. The X-ray intensity data were measured on a Bruker 
APEX-II CCD system equipped with a graphite monochromator and a MoKα sealed tube (λ 
= 0.71073 Å). Data collection temperature was 150 K. 
The total exposure time was 16.72 hours. The frames were integrated with the Bruker SAINT 
software package using a narrow-frame algorithm. The integration of the data using a 
monoclinic unit cell yielded a total of 116519 reflections to a maximum θ angle of 25.00° 
(0.84 Å resolution), of which 21005 were independent (average redundancy 5.547, 
completeness = 99.9%, Rint = 3.15%, Rsig = 2.19%) and 16835 (80.15%) were greater than 
2σ(F2). The final cell constants of a = 29.339(3) Å, b = 13.8631(13) Å, c = 29.715(3) Å, β = 
99.2288(16)°, V = 11930.(2) Å3, are based upon the refinement of the XYZ-centroids of 9901 
reflections above 20 σ(I) with 4.649° < 2θ < 56.33°. Data were corrected for absorption 
effects using the multi-scan method (SADABS). The calculated minimum and maximum 
transmission coefficients (based on crystal size) are 0.9526 and 0.9759. 
The structure was solved and refined using the Bruker SHELXTL Software Package, using 
the space group P 1 21/n 1, with Z = 4 for the formula unit, C100H155N32O49.50. The final 
anisotropic full-matrix least-squares refinement on F2 with 1867 variables converged at R1 = 
5.88%, for the observed data and wR2 = 12.11% for all data. The goodness-of-fit was 1.008. 
The largest peak in the final difference electron density synthesis was 0.798 e-/Å3 and the 
largest hole was -0.470 e-/Å3 with an RMS deviation of 0.057 e-/Å3. On the basis of the final 
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XPREP Version 2008/2 (G. M. Sheldrick, Bruker AXS Inc.)  
XS Version 2008/1 (G. M. Sheldrick, Acta Cryst. (2008). A64, 112-122)  
XL Version 2008/4 (G. M. Sheldrick, Acta Cryst. (2008). A64, 112-122)  
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Table 1. Sample and crystal data for UM2316a.  
Identification code 2316a 
Chemical formula C100H155N32O49.50 
Formula weight 2597.56 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal size 0.21 × 0.30 × 0.42 mm 
Crystal habit colorless prism 
Crystal system monoclinic 
Space group P 1 21/n 1 
Unit cell dimensions a = 29.339(3) Å α = 90° 
 b = 13.8631(13) Å β = 99.2288(16)° 





Volume 11930.(2) Å3  
Z 4 
Density (calculated) 1.446 Mg/cm3 
Absorption coefficient 0.117 mm-1 
F(000) 5500 
 
Table 2. Data collection and structure refinement for UM2316a.  
Diffractometer Bruker APEX-II CCD 
Radiation source sealed tube, MoKα 
Theta range for data 
collection 
2.07 to 25.00° 
Index ranges 
-34 ≤ h ≤ 34, -16 ≤ k ≤ 16, -35 ≤ l ≤ 
35 
Reflections collected 116519 
Independent reflections 21005 [R(int) = 0.0315] 
Coverage of independent 
reflections 
99.9% 
Absorption correction multi-scan 
Max. and min. transmission 0.9759 and 0.9526 
Structure solution technique direct methods 
Structure solution program SHELXS-97 (Sheldrick, 2008) 





Refinement program SHELXL-97 (Sheldrick, 2008) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 
21005 / 440 / 1867 
Goodness-of-fit on F2 1.008 
Δ/σmax 0.009 
Final R indices 
16835 data; 
I>2σ(I) 
R1 = 0.0588, wR2 = 
0.1160 
 all data 





Extinction coefficient 0.0002(0) 
Largest diff. peak and hole 0.798 and -0.470 eÅ-3 
R.M.S. deviation from mean 0.057 eÅ-3 
 
Rint = Σ|Fo2 - Fo2(mean)| / Σ[Fo2]  
R1 = Σ||Fo| - |Fc|| / Σ|Fo|  
GOOF = S = {Σ[w(Fo2 - Fc2)2] / (n - p)}1/2  






Details of the X-ray crystallographic structure of II-2f.  A colorless plate-like specimen of 
C50H94.28Cl4N20O25.14, approximate dimensions 0.18 mm × 0.44 mm × 0.48 mm, was used for 
the X-ray crystallographic analysis. The X-ray intensity data were measured on a Bruker 
APEX-II CCD system equipped with a graphite monochromator and a MoKα sealed tube (λ 
= 0.71073 Å). Data collection temperature was 150 K. 
The total exposure time was 22.73 hours. The frames were integrated with the Bruker SAINT 
software package using a narrow-frame algorithm. The integration of the data using a 
monoclinic unit cell yielded a total of 118279 reflections to a maximum θ angle of 30.00° 
(0.71 Å resolution), of which 39291 were independent (average redundancy 3.010, 
completeness = 99.5%, Rint = 4.30%, Rsig = 4.63%) and 34631 (88.14%) were greater than 
2σ(F2). The final cell constants of a = 13.7177(10) Å, b = 27.048(2) Å, c = 18.9817(14) Å, β 
= 92.5526(12)°, V = 7035.9(9) Å3, are based upon the refinement of the XYZ-centroids of 
9755 reflections above 20 σ(I) with 4.685° < 2θ < 61.03°. Data were corrected for absorption 
effects using the multi-scan method (SADABS). The calculated minimum and maximum 
transmission coefficients (based on crystal size) are 0.8858 and 0.9549. 
The structure was solved and refined using the Bruker SHELXTL Software Package, using 
the space group P 1 21 1, with Z = 4 for the formula unit, C50H94.28Cl4N20O25.14. The final 
anisotropic full-matrix least-squares refinement on F2 with 1686 variables converged at R1 = 
5.29%, for the observed data and wR2 = 12.34% for all data. The goodness-of-fit was 1.011. 
The largest peak in the final difference electron density synthesis was 0.689 e-/Å3 and the 
largest hole was -0.916 e-/Å3 with an RMS deviation of 0.071 e-/Å3. On the basis of the final 
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SAINT Version 7.68A (Bruker AXS Inc., 2009)  
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Table 1. Sample and crystal data for UM2349.  
Identification code 2349 
Chemical formula C50H94.28Cl4N20O25.14 
Formula weight 1519.77 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal size 0.18 × 0.44 × 0.48 mm 
Crystal habit colorless plate 
Crystal system monoclinic 
Space group P 1 21 1 
Unit cell dimensions a = 13.7177(10) Å α = 90° 
 b = 27.048(2) Å β = 92.5526(12)° 





Volume 7035.9(9) Å3  
Z 4 
Density (calculated) 1.435 Mg/cm3 
Absorption coefficient 0.259 mm-1 
F(000) 3214 
 
Table 2. Data collection and structure refinement for UM2349.  
Diffractometer Bruker APEX-II CCD 
Radiation source sealed tube, MoKα 
Theta range for data 
collection 
2.28 to 30.00° 
Index ranges 
-19 ≤ h ≤ 19, -36 ≤ k ≤ 38, -26 ≤ l ≤ 
26 
Reflections collected 118279 
Independent reflections 39291 [R(int) = 0.0430] 
Coverage of independent 
reflections 
99.5% 
Absorption correction multi-scan 
Max. and min. transmission 0.9549 and 0.8858 
Structure solution technique direct methods 
Structure solution program SHELXS-97 (Sheldrick, 2008) 





Refinement program SHELXL-97 (Sheldrick, 2008) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 
39291 / 31 / 1686 
Goodness-of-fit on F2 1.011 
Δ/σmax 0.001 
Final R indices 
34631 data; 
I>2σ(I) 
R1 = 0.0529, wR2 = 
0.1210 
 all data 








Largest diff. peak and hole 0.689 and -0.916 eÅ-3 
R.M.S. deviation from mean 0.071 eÅ-3 
 
Rint = Σ|Fo2 - Fo2(mean)| / Σ[Fo2]  
R1 = Σ||Fo| - |Fc|| / Σ|Fo|  
GOOF = S = {Σ[w(Fo2 - Fc2)2] / (n - p)}1/2  











 Chapter 3. Acyclic Cucurbit[n]uril-Type Molecular Containers: 
Influence of Aromatic Walls on their Function as Solubilizing 
Excipients for Insoluble Drugs 
 
3.1 Introduction 
In chapter 2, we studied the influence of the nature of the solubilizing groups (e.g. SO3- vs. 
OH vs NH3+) on the ability of acyclic CB[n] type containers to act as solubilizing agents for 
insoluble drugs and found that sulfonate groups are particularly well suited for this 
application because they impart high solubility in water and do not promote self-folding and 
complexation (e.g. as NH3+ does).80  In this chapter we explore the influence of the nature of 
the aromatic sidewalls on the ability of the acyclic CB[n]-type containers (III-1a – III-1e, 
Scheme III-1) to act as solubilizing agents for insoluble drugs. 
 
3.2 Results and discussion. 
This results and discussion section is organized as follows.  First, we describe the synthesis 
and solubility of two new acyclic CB[n]-type receptors III-1d and III-1e.  Next, we 
investigate the self-association properties of III-1a – III-1e.  Subsequently, we create phase 
solubility diagrams for III-1a – III-1e toward a range of well-known poorly soluble 
pharmaceutical agents (Figure III-2) and analyze trends in the solubilization data. 
 






Previously, we reported the synthesis and application of acyclic CB[n] type containers III-1a 
– III-1c by the double electrophilic aromatic substitution reaction of glycoluril tetramer 
bis(cyclic ether) building block III-2 with the corresponding dialkoxyaromatic sidewalls III-
3 in hot CF3CO2H.30,35,80  Compounds III-1a – III-1e differ in the nature of their aromatic 
sidewalls (e.g. benzene vs naphthalene) which impact the structure of the uncomplexed 
container and therefore their ability to act as a host and solubilizing agent for insoluble drugs.  
For example, the x-ray crystal structures of III-1a shows that the tips of the substituted 
benzene sidewalls are in close contact with one another.35  Therefore, to accommodate the 
longer naphthalene sidewalls of III-1b, the glycoluril tetramer backbone of III-1b flexes 
which results in a larger cavity which is defined in larger part by the aromatic naphthalene 
sidewalls.35  Compound III-1c is an isomer of III-1b; in this case the sidewalls are shorter 
and deeper by virtue of the attachment at the naphthalene 1,8 positions.30  To prepare new 
acyclic CB[n] type receptors III-1d and III-1e we needed to prepare aromatic sidewalls III-
3d and III-3e.  Accordingly, we reacted 2,3-dimethylhydroquinone with 1,3-propanesultone 
(III-4) under basic conditions (NaOH) in dioxane at room temperature to give III-3d in 73% 
yield (Scheme III-1a).  Sidewall III-3e was prepared by a multistep procedure (Scheme III-
1b).  First, we performed the Diels-Alder reaction between benzoquinone and 1,3-butadiene 
in toluene to give III-5 in 92% yield.124  Next, we aromatized III-5 by treatment with HBr to 
give III-6 in 82% yield.124  Subsequently, we reduced the double bond of III-6 under 
standard conditions to give III-7 in 85% yield.125  Finally, III-7 was reacted with III-4 under 





glycoluril tetramer III-2 with sidewall III-3d (4 equiv.) in a 1:1 (v:v) mixture of TFA:Ac2O 
at 70 ˚C gave acyclic CB[n] type container III-1d in 43% yield.  Similarly, the reaction of 
III-2 with III-3e (4 equiv.) gave container III-1e in 30% yield. 
 
Scheme III-1.  Structures of known acyclic CB[n] solubilizing excipients III-1b and III-1c 
and synthesis of III-1d and III-1e. 
 
3.2.2 Solubility Properties of the Acyclic CB[n] Type Containers III-1a – 
III-1e. 
An important property of a container that is to be used as a solubilizing excipient for 
insoluble drugs is the inherent solubility of the container alone.  Previously, we have reported 
the solubility of III-1a and III-1b in 20 mM sodium phosphate buffered D2O at pD 7.4 as 
105 mM and 14 mM, respectively.  We used the methodology reported previously35,80 – 1H 
NMR assay in the presence of 1,3,5-benzene tricarboxylic acid as internal standard of known 





mM), and III-1e (145 mM).  The high solubilities of III-1a, III-1c, III-1d, and III-1e make 
them particularly attractive as solubilizing excipients for insoluble drugs. 
 
3.2.3 Self-Association Properties of Acyclic CB[n] Type Containers III-1a – 
III-1e.   
Previously, we have investigated the self-association of III-1a and III-1b by dilution 
experiments monitored by 1H NMR spectroscopy.  We found that the observed changes in 
chemical shift for each container fit well to a 2-fold self association model and extracted the 
corresponding self-association constants (III-1a, Ks = 47 M-1; III-1b, Ks = 624 M-1).35,117  
Because III-1a and III-1b have a low propensity to self-associate they are well suited to act 
as solubilizing excipients for insoluble drugs.  In a similar manner, we performed the 1H 
NMR dilution experiment (15 mM – 0.1 mM) for III-1d and measured the corresponding 
value of Ks for III-1d as 130 M-1.  When we performed similar 1H NMR dilution experiments 
for III-1c we unexpectedly observed two sets of resonances that were in slow exchange on 
the chemical shift timescale.  We measured the diffusion coefficients for these two species by 
DOSY NMR spectroscopy (D = 2.058 and 1.751 x 10-10 m2/s, Supporting Information) which 
allows us to conclude that the two species correspond to monomer III-1c and dimer (III-1c)2.  
Accordingly, we integrated the resonances for the two species at several different 
concentrations and determined the value of Ks (372 M-1) in the usual manner.94  Finally, we 
performed a dilution experiment for III-1e (35 mM – 0.2 mM) and observed both broadening 
and changes in 1H NMR chemical shifts.  Unfortuantely, the changes in chemical shift could 





undergoes more complex higer order aggregation.  The generally weak self-association 
observed for III-1a – III-1e are advantageous toward their use as solubilizing excipients for 
insoluble drugs because the container is free to associate with drug without having to 
overcome strong self-assocation. 
 
3.2.4 Theoretical Treatment of Phase Solubility Diagrams. 
 
Figure III-1.  Chemical structures of drugs used in this study. 
 
Phase solubility diagrams (PSD) – plots of [Drug] as a function of [Container] are commonly 
used to study the ability of molecular containers to increase the solubility of insoluble 
drugs.52,117  These phase solubility diagrams can assume a variety of shapes, but linear PSDs 
(AL type) are most common and occur when container and guest form well defined 1:1 
container•guest complexes.  Such PSDs behave according to equation III-1 where S0 is the 
solubility of drug alone, Ka is the binding constant for the container•drug complex, and slope 





performed on a hypothetical container•drug system that obeys equation III-1 to stimulate the 
discussion and analysis of the experimental PSDs created for containers III-1a– III-1e and 
HP- β-CD with drugs III-8 – III-26 shown in Figure III-2.  Figure III-3a shows the 
calculated PSDs for five different containers and a single drug with S0 = 1 x 10-6 M which 
form well defined 1:1 container•drug complexes of high solubility.  The different Ka values 
for the different container•drug complexes translate into PSDs with different slopes.  For 
example, a change in slope from 0.1 to 0.5 and from 0.5 to 0.9 each correspond to a 9-fold 
increase of Ka.  Importantly, a precise knowledge of S0 is not necessary in order to calculate 
relative Ka values (Krel = Ka,C1•D1 / Ka,C2•D1) from the PSDs obtained with two different 
containers (e.g. C1 and C2) toward a common drug (e.g. D1) because the S0 values cancel as 
shown in equation III-2.  If S0 is known precisely, then absolute Ka values can be calculated 
using equation III-1.  Figure III-3b shows a plot of the slope of the PSD as a function of the 
Ka for the container•drug complex for five different values of S0 (1 mM, 100 µM, 10 µM, 1 
µM, 100 nM).  Clearly, the lower the inherent solubility of the drug (S0), the higher the value 
of Ka needed to result in a PSD of comparable slope.  As a special case of equation III-1, 
consider the situation when (Ka)(S0) = 1; under this constraint, then slope = 0.5 (Figure III-
3b)     From a practical point of view this means that to efficiently solubilize an insoluble 
drug (e.g. slope of PSD = 0.5) with an inherent solubility of 10 mM (100 nM) requires a Ka 
value of 105 M-1 (107 M-1).  In theory, the high values of Ka that are typically observed for 
CB[n]-type receptors promise to enable the solubilization of drugs whose solubilities are too 
low to be solubilized by lower affinity hosts (e.g. cyclodextrins). 








    (III-2) 
 
Figure III-2.  Simulations of the phase solubility behavior of hypothetical container•drug 1:1 
systems that obey equation III-1.  a) Plot of [Drug] versus [Container] for a system with S0 = 
1 µM and five different Ka values. B) Plot of slope of the PSD versus Ka (M-1) for five 

















3.2.5 Use of III-1a – III-1e as Solubilizing Agents for Insoluble Drugs. 
 
Table III-1.  Inherent solubility (S0) of selected drugs and values of slope calculated from the 
linear region of the PSDs for containers III-1a – III-1e and HP- β-CD with drugs III-8 – III-
26.  The corresponding Ka (M-1) and Krel values were calculated using equations III-1 and 
III-2. 




Krel          
Ka 
Slope Krel          Ka 
Slope Krel          Ka 
Slope Krel          Ka 
Slope Krel          Ka 
Slope Krel          Ka 
III-
8 n.d. n.l. – 0 – 0 – 0 – 0 – 0 – 
III-
9 












10 n.d. 0.774 27.055 1.053 TL 0.814 34.549 0.801 31.686 0.467 6.898 0.113 1 
III-
11 












12 n.d. 0.588 632.642 0 – 0 – 0 – 0.057 26.580 0.002 1 
III-


















15 n.d. 0.024 1.846 0.473 66.589 0.022 1.694 0.017 1.269 0 – 0.013 1 
III-
16 












17 n.d. 0.711 14.761 0.919 67.764 0.143 1 0.517 6.434 0.159 1.132 0 – 
III-
18 












19 n.d. 0.353 1 1.085 TL 0.405 1.247 0.383 1.138 0.439 1.437 0.469 1.620 
III-
20 n.d. 0 – 0 – 0.121 8.569 0.016 1 0.021 1.317 0 – 
III-
21 












22 n.d. 0 – n.l. – 0 – 0 – 0 – 0 – 
III-
23 n.d. 0.079 1 0 – 0 – 0 – 0 – 0 – 
III-
24 












25 n.d. 0 – 0.104 1 0 – 0 – 0 – 0 – 
III-
26 









n.d. = not determined, n.l. = non-linear PSD; – = could not be determined because PSD is 
non-linear or slope = 0; TL = too large to be determined from PSD. 
 
In order to more fully understand the correlation between container structure (e.g. III-1a – 
III-1e), drug structure and properties, and the ability of the containers to solubilize insoluble 
drugs we created phase solubility diagrams (PSD) for containers III-1a – III-1e and HP- β-





currently used in practice along with PBS-1086 which is a developmental compound with 
documented anti-cancer activity.126  To create these PSDs we stir an excess of insoluble drug 
with a known concentration of container until equilibrium is achieved, then remove 
remaining insoluble drug by filtration or centrifugation, and measure the concentration of 
drug in the supernatant by 1H NMR spectroscopy.  Our 1H NMR assay relies on the addition 
of a known concentration of 1,3,5-benzene tricarboxylic acid as a non-binding internal 
standard of known concentration which allows us to use the ratio of the integrals for drug 
versus internal standard to measure drug concentration.  We have measured full PSDs for all 
19 drugs with the six containers (Supporting Information).  In nearly all cases, linear PSDs 
were observed at low [container] indicative of well defined 1:1 complex formation, although 
some of the PSDs display plateau regions at higher [container] which indicates that the 
solubility of the container•drug complex is lower than that of uncomplexed container.  Table 
III-1 gives the initial slopes of the PSDs determined by linear regression for all container-
drug combinations.  Table III-1 also presents the Krel values calculated using equation III-2 
referenced to the weakest bind host (usually HP- β-CD).  Figure III-4 presents the PSDs 
measured for three drugs (Estradiol, PBS-1086, Camptothecin) with the 6 different 
containers.  In the sections below, we analyze the data presented in Table III-1 to ascertain 
key features of the use of acyclic CB[n]-type containers as solubilizing excipients for 
insoluble drugs. 
 
Container III-1b is the Most Potent Solubilizing Agent.  Of the 19 drugs tested, compound 





nearly the best for two additional drugs (slopes for voriconazole: III-1b = 0.893 versus III-1e 
= 0.895; slopes for ziprasidone: III-1b = 0.432 versus III-1e = 0.458).  For four drugs 
(melphalan, amiodarone, camptothecin, 17a-ethynylestradiol), III-1b forms such tight 
complexes (slope ≈ 1) that it is not possible to calculate a Krel value using equation III-1.  To 
understand the superior binding properties of III-1b we performed MMFF minimizations of 
the complexes between truncated versions of III-1a – III-1e  (OMe instead of 
O(CH2)3SO3Na arms) and trans-1,4-cyclohexane diammonium ion (Figure III-5) to assess the 
geometrical features of the complexes.  As can readily be seen, container III-1a features the 
smallest cavity (distances between opposing glycoluril methine C-atoms = 10.90 and 10.38 
Å) whereas the corresponding distances for III-1b – III-1e are substantially longer.  
Container III-1b features the largest cavity (opposing C-atom distance = 12.34 and 11.42 Å) 
and its naphthalene walls engage in a perfect edge-to-face p-p interaction which provides a 
large hydrophobic p-surfaces to engage in π−π interactions with aromatic drugs.  Although 
the cavity size of containers III-1d and III-1e are comparable to that of III-1b they are partly 
shaped by the CH3 groups and fused cyclohexyl rings reduce the available p-surface area.  
We surmise these are the reasons behind the superior binding abilities of III-1b. 
 
Solubilization of Steroids.  The test panel of insoluble drugs contained three steroids 
(estradiol, 17-a-ethynylestradiol, and fulvestrant).  Steroids can often be solubilized with HP-
β-CD, which allows a head-to-head comparison with our acyclic CB[n]-type containers.  
Figure III-4a shows the PSDs measured for all six containers toward estradiol which is 





efficiently (slope = 0.354 to 0.92; Krel from 2.4 to 50.5) than HP-β-CD (slope = 0.185; Krel = 
1).  Figure III-6a-c shows the 1H NMR spectra recorded for estradiol alone in DMSO-d6 and 
in the presence of III-1a and III-1b in buffered D2O.  The large upfield shifts observed for 
the axial Me-group (Hk) and the protons on the sp3-hydridized C-atoms of the steroidal 
skeleton indicate that the containers bind preferentially to this region of the steroids.  
Container III-1b solubilizes 17-a-ethynylestradiol with 1:1 stoichiometry which is indicative 
of a very large association constant Ka for this complex.  Only container III-1b was capable 
of solubilizing fulvestrant which is both highly hydrophobic and fluorinated.  Previously, we 
have established that III-1b binds to the neuromuscular blocking agents rocuronium and 
vecuronium which are steroidal diammoniums with Ka > 109 M-1.112 In combination, these 
results allow us to conclude that acyclic CB[n]-type containers – but especially III-1b – are 






Figure III-3.  Phase solubility diagrams constructed for mixtures of containers (III-1a, ; 
III-1b, o; III-1c, ¸; III-1d, ¿; III-1e, r; HP-β-CD,p) with selected insoluble drugs: a) 
Estradiol, b) PBS-1086, c) Camptothecin.  Conditions: 20 mM sodium phosphate buffered 






Figure III-4.  MMFF minimized models of the trans-1,4-cyclohexanediammonium ion 
complexes of truncated versions (OMe rather than O(CH2)3SO3Na arms) of: a) III-1a, b) III-
1b, c) III-1c, d) III-1d, e) III-1e.  The distances between the labeled (• and •) glycoluril 
quaternary C-atoms are given in Å. 
 
Developmental Anticancer Agent PBS-1086.  PBS-1086 is a developmental drug with 
documented in vivo anticancer activity using a DMSO formulation, but which could not be 
formulated in water using the standard techniques including cyclodextrins.126  Accordingly, 
we decided to investigate the formulation of PBS-1086 using container III-1a – III-1e (Table 
III-1 and Figure III-4b).  All five acyclic CB[n]-type containers solubilize PBS-1086 (slope = 
0.143 to 0.919) whereas HP-β-CD is incapable of solubilizing this drug.  Interestingly, 
although PBS-1086 is most efficiently solubilized by III-1b (slope = 0.919), container III-1a 





the higher inherent solubility of III-1a.  PBS-1086 is also nicely solubilized by III-1d which 
is perhaps unsurprising given that the Me-substituted sidewalls of III-1d makes it 
intermediate in size (Figure III-5) between III-1a and III-1b. 
 
Figure III-5.  1H NMR recorded (400 MHz, RT, 20 mM sodium phosphate buffered D2O, 
pH 7.4) for: a) estradiol (in DMSO-d6), b) III-1a (10 mM) with estradiol, c) III-1b (10 mM) 
with estradiol, d) camptothecin (in DMSO-d6), e) III-1d (15 mM) with camptothecin, and f) 
III-1b (10 mM) with camptothecin. 
 
Acyclic CB[n]-type Containers are Good Solubilizing Agents for Insoluble Drugs Containing 
Aromatic Rings.  The molecular models of III-1a – III-1e show that the aromatic sidewalls 
are oriented at approximately right angles to one another which defines a hydrophobic box.  





good guests for acyclic CB[n]-type containers.  The majority of drugs studied in this paper 
contain aromatic rings within their structure and we generally observed upfield shifting of the 
1H NMR resonances of these aromatic rings upon complexation with III-1a – III-1e.  Those 
aromatic rings with attached ammonium functional groups (e.g. anilines, benzimidazoles, N-
arylpiperazines) constitute preferred binding sites.  In only one case (amiodarone, III-13) was 
complexation at an aliphatic ammonium (Pr2NHR+) moiety predominant.  The observed 
upfield shifting of the aromatic protons confirms that the aromatic residues of the drugs are 
encapsulated within the hydrophobic box that is defined by the two aromatic walls and the 
methylene bridged glycoluril tetramer backbone.  For example, Figure III-6d-f shows the 1H 
NMR spectra recorded for camptothecin alone in DMSO-d6 and in water in the presence of 
containers III-1d and III-1b.  Obviously, the protons on the aromatic rings of camptothecin 
(Ha – Hf) undergo substantial upfield shifts upon complexation.  Larger upfield shifts are 
observed upon complexation with III-1b probably because of the larger anisotropic effect of 
the naphthalene walls of III-1b relative to the o-xylylene walls of III-1d.  Figure III-4c 
shows the PSDs created for mixtures of camptothecin with containers III-1a – III-1e and 
HP-β-CD which display AL-type PSDs indicative of 1:1 complexation.  All five acyclic 
CB[n]-type containers (III-1a – III-1e) solubilize camptothecin nicely, with III-1b doing so 
in equimolar amounts whereas HP-β-CD is unable to solubilize camptothecin under these 
conditions.  We believe that the strategic merging of the structural features of CB[n] 
receptors (to deliver strong hydrophobic binding and ammonium binding) with the aromatic 
walls of cyclophanes to impart affinity toward the wide variety of insoluble aromatic drugs 





cyclodextrins that expands the scope of insoluble drugs that can be formulated with 
molecular container technology. 
 
Some Drugs are Solubilized by a Narrow Set of Containers.  Four drugs are solubilized by 
only one acyclic CB[n]-type container: paclitaxel and docetaxel by III-1a, fenofibrate and 
fulvestrant by III-1b.  Cinnarizine is only solubilized by two containers; it is best solubilized 
by III-1a and less well by III-1e.  Based on this data we believe that containers III-1a and 
III-1b are the most versatile and general purpose solubilizing agents and that these containers 
are best positioned for further development as novel solubilizing excipients for practical 
applications. 
 
Container III-1d is Structurally and Functionally Intermediate Between III-1a and III-1b.  
The dimethyl substituted o-xylylene walls  of container III-1d are intermediate in length 
between III-1a and III-1b which feature benzene and napthalene derived sidewalls.  
Compound III-1d is also intermediate between III-1a and III-1b in terms of its self-
association properties but possesses superior solubility characteristics (353 mM) in buffered 
water.  Figure III-5 shows that the difference in length of the aromatic walls of III-1d also 
results in a cavity that is intermediate between those of III-1a  and III-1b.  Accordingly, and 
perhaps unsurprisingly, we find that III-1d exhibits solubilization abilities that are similar to 
those of III-1a and III-1b.  For example, for albendazole, melphalan, amiodarone, 
indomethacin, and tolfenamic acid the slopes and Krel values for III-1d are comparable to 





For other drugs, namely voriconazole and ziprasidone, the slope and Krel values measured for 
III-1d are more comparable to those of III-1b than III-1a. 
 
3.2.6 Comparison of the Binding Affinity of III-1a – III-1e with HP-β-CD 
Toward Insoluble Drugs. 
It is also possible to determine the absolute Ka value for container•drug complexes from the 
PSDs if the solubility of the uncomplexed drug (S0) is known.  Accordingly, we measured the 
inherent solubility for 8 drugs (albendazle, tamoxifen, camptothecin, tolfenamic acid, 
estradiol, aripiprazole, voriconazole, and ziprasidone) and used these S0 values to determine 
the absolute Ka values for this selection of drugs as given in Table III-1.  The binding 
constants for these eight drugs toward HP-β-CD span the range of 415 to 24300 M-1 which is 
in line with the well-known low affinity (log Ka = 2.5 ± 1.1 M-1) and low selectivity of 
cyclodextrins toward their guests.127,128  In contrast, the Ka values measured for these 8 drugs 
toward III-1a – III-1e fall in the range of 1300 to 1.2 x 106 M-1 with two additional 
complexes being too tight to measure using the PSD.  The best acyclic container (e.g. III-1a 
– III-1e) always forms significantly stonger container•drug complexes (29 to 152-fold 
stronger).  In many cases the acyclic containers bind to and solubilize drugs (e.g. 
camptothecin and aripiprazole) that cannot be solubilized at all with HP- β-CD.  The ability 
of III-1a – III-1e to solubilize drugs that cannot be solubilized with HP- β-CD and to do so 
more efficiently (larger slope and Ka) suggests that acyclic CB[n]-type containers will 







In summary, we have compared the ability of III-1a – III-1e to solubilize insoluble drugs 
relative to HP- β-CD.  Compounds III-1a – III-1e do not undergo strong self-association (Ks 
≤ 624 M-1) in buffered water and possess good solubility characteristics.  We created phase 
solubility diagrams for mixtures of containers III-1a – III-1e and HP- β-CD with 19 drugs. 
We find that the solubilizing ability of the best container (III-1a – III-1e) is superior to HP-
 β-CD in all cases; III-1a – III-1e even solubilize 8 drugs that are completely insoluble with 
HP- β-CD.  The superior solubilizing ability can be traced to the 29 to 152-fold higher 
binding affinity of the best acyclic CB[n]-type container toward the drugs compared to HP-
 β-CD.  Less container is needed, therefore, to achieve a given [drug].  A notable 
achievement was the solubilization of the developmental anticancer agent PBS-1086. The 
acyclic CB[n]-type containers display an affinity for the steroid ring system, aromatic 
moieties of insoluble drugs, and cationic ammonium groups.  Compound III-1b is generally 
the most potent (Ka up to and exceeding 106 M-1) container whereas both III-1a and III-1b 
display excellent solubility enhancement toward a broad range of insoluble drugs.  The broad 
scope of insoluble drugs that can be formulated with III-1a and III-1b – in many cases where 
HP- β-CD fails completely – makes acyclic CB[n]-type containers particularly attractive 
alternatives to cyclodextrins as solubilizing excipients for practical applications. 
 
3.4 Experimental Section. 
General Experimental.  Starting materials were purchased from commercial suppliers and 





Compounds III-1a – III-1c, III-2, III-5 and III-6 were prepared according to literature 
procedures.30,35,124  Melting points were measured on a Meltemp apparatus in open capillary 
tubes and are uncorrected. IR spectra were measured on a JASCO FT/IR 4100 spectrometer 
and are reported in cm-1. NMR spectra were measured at 400 MHz or 600 MHz for 1H and 
125 MHz for 13C. Mass spectrometry was performed using a JEOL AccuTOF electrospray 
instrument using the electrospray ionization (ESI) technique. 
 
Compound III-3d. A solution of III-4 (18.409 g, 150 mmol) in 1,4-dioxane (130 mL) was 
added into a solution of 2,3-dimethylhydroquinone (8.005 g, 57.9 mmol) in aqueous NaOH 
solution (1.00 M, 100 mL). The mixture was stirred at RT for 12 h then filtered to collect the 
crude solid. The solid was stirred with acetone (200 mL) then dried under high vacuum to 
yield III-3d as a pale red solid (18.007 g, 73%).  M.p. > 280 ˚C. IR (ATR, cm-1): 2938w, 
2869w, 1625m, 1489m, 1472m, 1205s, 1157s, 1112s, 1059s, 801m, 624m, 551m.  1H NMR 
(400 MHz, D2O): δ 6.88 (s, 2H), 4.10 (t, J = 5.6, 4H), 3.10 (t, J = 7.2, 4H), 2.15 - 2.05 (m, 
8H), 1.71 (s, 6H).  13C NMR (125 MHz, D2O, 1, 4-dioxane as internal reference): δ 150.5, 
127.6, 111.8, 68.2, 47.6, 24.1, 11.1.  High-Res MS (ESI): m/z 381.0694 ([M – 2Na + H]-, 
C14H21O8S2, calculated for 381.0678). 
 
Compound III-7. A solution of III-6 (5.315 g, 32.8 mmol) in EtOH (160 mL) was mixed 
with palladium on activated carbon (3.510 g, 10 wt. %, 3.3 mmol).  The mixture was stirred 
under H2 gas (15 Psi) for 3 days at RT. The slurry was then filtered and the filtrate was 





vacuum, the product was obtained as a light purple solid (4.57 g, 85%).  Characterization data 
matches the literature report.19 
 
Compound III-3e. A solution of III-4 (8.580 g, 69.8 mmol) in 1,4-dioxane (60 mL) was 
added into a solution of III-7 (4.000 g, 27.9 mmol) in aqueous NaOH solution (1.00 M, 45 
mL). The mixture was stirred at RT for 12 h then filtered to collect the crude solid. The crude 
solid was stirred with acetone (100 mL) then dried under high vacuum to yield III-3e as a 
white solid (7.570 g, 60%).  M.p. > 280 ˚C. IR (ATR, cm-1): 2946w, 2846w, 1652w, 1471w, 
1256m, 1194s, 1094m, 1045s, 791w, 604w, 521w.  1H NMR (400 MHz, D2O): δ 6.83 (s, 
2H), 4.09 (t, J = 6.0, 4H), 3.08 (t, J = 6.2, 4H), 2.65 - 2.55 (m, 4H), 2.35 – 2.15 (m, 4H), 1.75 
– 1.60 (m, 4H).  13C NMR (125 MHz, D2O, 1, 4-dioxane as internal reference): δ 150.0, 
128.1, 110.2, 67.4, 47.6, 24.0, 22.7, 21.2.  High-Res MS (ESI): m/z 407.0842 ([M – 2Na + 
H]-, C16H23O8S2, calculated for 407.0834). 
 
Container III-1d. Compound III-3d (0.658 g, 1.55 mmol) was added into a solution of III-2 
(0.300 g, 0.38 mmol) in TFA/Ac2O (3.0 mL, v/v = 1:1).  The mixture was stirred and heated 
at 70 ˚C for 3 h. The solvent was removed with under reduced pressure and the solid was 
further dried under high vacuum.  The solid was recrystallized with the mixture of water and 
EtOH (1:2, v/v, 20 mL) twice and then dissolved in water and adjusted to pH = 7 with 1 M 
aqueous NaOH. The solvent was removed under reduced pressure and then the solid was 
further dried under high vacuum to yield III-1d as a white solid (0.262 g, 43%).  M.p. > 300 





1185s, 1093m, 1044s, 960w, 823w, 800m, 795m.  1H NMR (400 MHz, D2O): δ 5.68 (d, J = 
15.3, 2H), 5.59 (d, J = 15.7, 4H), 5.43 (d, J = 7.8, 2H), 5.36 (d, J = 7.8, 2H), 5.17 (d, J = 
16.1, 4H), 4.35 (d, J =16.1, 4H), 4.25 (d, J = 15.7, 4H), 4.07 (d, J = 15.3, 2H), 4.00 – 3.80 
(m, 4H), 3.75 – 3.55 (m, 4H), 3.25 -3.05 (m, 8H), 2.25 – 2.15 (m, 8H), 1.82 (s, 12H), 1.78 (s, 
6H), 1.74 (s, 6H).  13C NMR (125 MHz, D2O, 1,4-dioxane as internal reference): δ 156.1, 
155.5, 149.7, 130.9, 127.6, 78.0, 76.9, 72.1, 70.7, 70.5, 52.1, 47.8, 47.3, 35.6, 24.3, 15.8, 
14.8, 11.8.  High-Res MS (ESI): m/z 753.1997 ([M – 4Na + 2H]2-, C58H74N16O24S4, 
calculated for 753.1972). 
 
Container III-1e.  Compound III-3e (1.160 g, 2.56 mmol) was added into a solution of III-2 
(0.500 g, 0.64 mmol) in TFA/Ac2O (5.0 mL, v:v = 1:1).  The mixture was stirred and heated 
at 70 ˚C for 3 h. The solvent was removed under reduced pressure and the solid was further 
dried under high vacuum.  The solid was recrystallized with the mixture of water and EtOH 
(1:2, v/v, 300 mL) twice and then dissolved in water and adjusted to pH = 7 by adding 1 M 
aqueous NaOH. The solvent was removed under reduced pressure and then the solid was 
further dried under high vacuum to yield III-1e as a white solid (0.301 g, 30%).  M.p. > 300 
oC.  IR (ATR, cm-1): 2930w, 2875w, 1724s, 1471s, 1375m, 1320m, 1233s, 1171s, 1084m, 
1041s, 824w, 801m, 759w.  1H NMR (400 MHz, D2O, with added p-xylenediamine): δ 5.64 
(d, J = 15.8, 4H), 5.49 (d, J = 15.5, 2H), 5.45 (d, J = 8.8, 2H), 5.28 (d, J = 8.8, 2H), 5.23 (d, J 
= 16.4, 4H), 4.38 (d, J =16.4, 4H), 4.29 (d, J = 15.8, 4H), 3.97 (d, J = 15.5, 2H), 4.00 – 3.80 
(m, 4H), 3.75 – 3.65 (m, 4H), 3.25 -3.15 (m, 8H), 2.65 – 2.50 (m, 4H), 2.30 – 2.15 (m, 12H), 





D2O, with added p-xylenediamine and 1,4-dioxane as internal reference): δ 156.5, 155,7, 
149.7, 132.0, 131.6, 127.8, 126.7, 78.3, 77.2, 71.7, 71.2, 71.0, 52.7, 48.4, 47.6, 41.6, 35.6, 
24.7, 22.9, 21.0, 15.5, 14.8.  High-Res MS (ESI): 779.2154 ([M-4Na+2H]2-, C62H78N16O24S4, 
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Figure S III-2. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 


















Figure S III-4. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 















Figure S III-6. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference) 








Figure S III-7. 1H NMR spectra (400 MHz, D2O, RT, excess p-xylenediammonium ion as 









Figure S III-8. 13C NMR spectra (125 MHz, D2O, RT, 1,4-dioxane as internal reference, 






Figure S III-9. Plots of the change in intensity of the indicated NMR resonances in the 
DOSY spectra as a function of magnetic field gradient recorded (600 MHz, D2O, 298K) for 
host III-1c and (III-1c)2. 
 
Figure S III-10. 1H NMR recorded (400 MHz, 20 mM NaD2PO4, pD = 7.4) for III-1c at 











Figure S III-11. 1H NMR recorded (400 MHz, 20 mM NaD2PO4, pD = 7.4) for for III-1d at 
varied concentration (0.1 – 15 mM) self-association study.  
 
 
Figure S III-12. Plot of chemical shift of III-1d versus [III-1d]. The solid line represents the 







Figure S III-13. 1H NMR recorded (400 MHz, 20 mM NaD2PO4, pD = 7.4) for III-1e at 






Procedure to measure the solubility of drugs with Host III-1a – III-1e. Excess amount of 
drug was added into a solution of host (III-1a – III-1e) of known concentration in deuterated 
sodium phosphate buffer (20 mM, pD = 7.4).  The suspended mixture was magnetically 
stirred at room temperature for 6 h. During this period, the pD value of the solution was 
monitored and adjusted back to 7.4 if it changed.  The mixture was then filtered. The 1H 
NMR spectrum of the supernatant was measured (400 MHz) with 1,3,5-benzenetricarboxylic 
acid (1.00 mM) as internal standard. The signal for the reference shows up at 8.35 ppm (s, 
3H). Diagnostic signals for the dissolved drug were also integrated. From the ratio of 
integrations of reference peak relative to the drug peak, and the concentration of reference, 
the concentration of the drug can be calculated.  
 
Procedure to measure the solubility of drugs with Host III-1c. Excess amount of drug was 
added into a solution of host III-1c of known concentration in deuterated sodium phosphate 
buffer (1.0 mL, 20 mM, pD = 7.4).  The suspended mixture was magnetically stirred at room 
temperature for 6 h. During this period, the pD value of the solution was monitored and 
adjusted back to 7.4 if it changed.  The mixture was then filtered, and 5 equivalents of 
spermine tetrahydrochloride salt was added as an aqueous solution.  The solvent was then 
removed from the mixture under reduced pressure, and the residue solid was extracted with 
EtOH (3.0 mL × 3).  The EtOH extracts was combined and solvent was removed under 
reduced pressure.  The residue was then dissolved in 1.0 mL deuterated DMSO, and the 1H 
NMR spectrum of the solution was measured (400 MHz) with 1,3,5-benzenetricarboxylic 





3H). Diagnostic signals for the dissolved drug were also integrated. From the ratio of 
integrations of reference peak relative to the drug peak, and the concentration of reference, 
the concentration of the drug can be calculated.  The chemical structures of drugs used in this 








Table SIII-1. Solubility enhancement of water-insoluble drugs (mM) with hosts III-1a – III-1c. 
 III-1a III-1b III-1c 
 [Host] [Drug] [Host] [Drug] [Host] [Drug] 
Taxol 
10 0.41 14 0 20 0 
15 0.66     
22 1.56     
33 2.24     
50 4.34     
90 11     
Albendazole 
10 1.87 1 0.62 2 0.17 
15 2.56 2 1.97 5 0.34 
22 3.54 4 2.22 10 0.51 
33 4.91 6 3.02 15 0.55 
50 6.74 8 4.48 25 0.82 
Melphalan 
6.6 9.2 4 5.6 2 0.3 
10 16.9 6 8.3 5 4.4 
15 24.1 8 9.7 10 8.2 
22 27 10 12.9 15 11.2 
33 31.5 14 16.1 25 13.5 
50 32     
90 36     
Tamoxifen 
1 0.04 1 0.22 2 1.44 
2 0.08 2 0.46 5 3.12 
3.5 0.14 4 0.54 10 5.18 
6.5 0.18 6 0.81 15 7.77 
12 0.21 8 0.98 25 12.1 
24 0.23 10 1.18   
Cinnarizine 
0.65 0.32 14 0 2 0 





2.6 1.47   10 0 
 
 III-1a III-1b III-1c 
 [Host] [Drug] [Host] [Drug] [Host] [Drug] 
Cinnarizine 
7.9 3.3   15 0 
23 4.4   25 0 
42 4.5     
69 4.6     
Amiodarone 
6.6 0.54 1 0.50 2 0.33 
10 0.75 2 1.15 5 0.63 
15 1.14 4 4.25 10 1.54 
22 2.28 6 5.31 15 1.93 
33 2.88 8 4.95 25 3.51 
50 3.9 10 5.1   
90 4     
Camptothecin 
2 0.21 1 1.04 2 0.82 
6 0.71 2 2.28 5 1.63 
8 0.89 4 3.68 10 2.99 
10 1.36 6 6.65 15 4.77 
25 1.82 8 8.47 25 6.56 
35 1.94 10 11.6   
Indomethacin 
2 0.11 1 2.35 2 0.11 
5 0.21 2 3.28 5 0.15 
10 0.33 4 4.44 10 0.22 
20 0.69 6 5.19 15 0.43 
50 1.28 8 6.15 25 0.51 
  10 6.70 35 0.87 
Tolfenamic 
acid 
2 0.07 1 0.7 2 0.05 





10 0.51 4 2.58 10 0.52 
25 1.11 6 3.4 15 0.76 
 
 III-1a III-1b III-1c 
 [Host] [Drug] [Host] [Drug] [Host] [Drug] 
Tolfenamic 
acid 
50 1.52 8 4.47 25 1.22 
  10 5.6   
PBS-1086 
1 0.89 2 1.77 2 1.03 
2 1.86 4 3.61 5 1.41 
4 3.2 8 6.11 10 2.4 
8 4.5 10 10.1 15 3.28 
15 8.29 14 12.5 25 4.21 
25 15.5     
60 43.1     
β-estradiol 
1 0.45 1.5 1.71 2 1.10 
2 0.85 2.5 2.73 5 1.96 
4 1.69 5 5.32 8 3.08 
6 2.01 10 10.5 10 5.52 
8 2.91 14 12.9 16 6.4 
10 3.75     
17α - 
ethynylestradiol 
1 0.51 1 0.85 2 1.12 
2 0.95 2 2.11 5 2.76 
4 1.77 4 3.67 8 3.22 
6 2.21 6 5.84 10 5.56 
8 3.17 8 8.78 15 6.22 
10 3.69 10 10.5   
Itraconazole 
20 0 14 0 2 0.45 
    5 0.66 





    20 2.92 







 III-1a III-1b III-1c 
 [Host] [Drug] [Host] [Drug] [Host] [Drug] 
Aripiprazole 
2 0.18 2 0.55 2 0.08 
5 0.31 4 1.45 5 0.21 
10 0.68 6 1.82 10 0.32 
15 1.01 8 2.32 15 0.57 
25 1.13 10 3.20 25 0.85 
Fenofibrate 
25 0 2 0.07 25 0 
  4 0.11   
  6 0.15   
  8 0.31   
  10 0.46   
Docetaxel 
2 0.55 14 0 25 0 
4 0.72     
6 1.02     
8 1.11     
10 1.36     
15 1.55     
Voriconazole 
2 0.82 2 1.94 2 0.67 
4 1.72 4 3.21 4 1.18 
6 2.31 6 5.88 6 2.52 
8 3.44 8 6.48 8 3.03 
10 4.92 10 9.23 10 3.69 
Fulvestrant 
50 0 2 0.08 25 0 
  4 0.29   
  6 0.43   
  8 0.71   
  10 0.91   






 III-1a III-1b III-1c 
 [Host] [Drug] [Host] [Drug] [Host] [Drug] 
Ziprasidone 
4 3.11 4 1.72 5 1.03 
6 6.88 6 2.59 10 1.82 
8 6.13 8 3.21 18 3.88 






Table SIII-2. Solubility enhancement of water-insoluble drugs (mM) with hosts III-1d, III-
1e, and HPCD. 
 III-1d III-1e HPCD 
 [Host] [Drug] [Host] [Drug] [Host] [Drug] 
Taxol 25 0 25 0 100 0 
Albendazole 
2 0.25 25 0 2 0.06 
5 0.53   5 0.11 
10 1.37   10 0.23 
20 2.11   50 0.71 
35 3.77   100 1.52 
Melphalan 
2 0.84 2 1.33 5 4.33 
5 3.61 5 2.67 10 5.58 
10 10.8 10 5.96 30 9.23 
20 14.5 20 12.3 50 10.3 
35 28.4 35 16.2 100 15.5 
Tamoxifen 
2 0.15 25 0 2 0.07 
5 0.33   10 0.33 
10 0.50   20 0.89 
15 0.94   30 1.17 
20 1.22   60 1.75 
    100 2.90 
Cinnarizine 
25 0 2 0.09 5 0.06 
  5 0.27 10 0.08 
  10 0.57 20 0.11 
  20 1.11 50 0.17 
  35 1.34 100 0.28 
Amiodarone 
2 0.44 2 0.18 2 0.22 
5 0.87 5 0.62 5 0.41 
10 1.39 10 1.36 10 1.24 





35 3.23 35 2.92 35 3.11 
 
 III-1d III-1e HPCD 
 [Host] [Drug] [Host] [Drug] [Host] [Drug] 
Camptothecin 
2 0.87 2 0.55 50 0 
5 1.82 5 1.13   
10 4.22 10 1.93   
30 15.1 15 2.52   
50 24.6 25 3.77   
Indomethacin 
2 0.06 25 0 5 0.15 
5 0.11   10 0.27 
10 0.27   30 0.55 
20 0.44   50 0.80 
35 0.61   100 1.44 
Tolfenamic 
acid 
2 0.11 25 0 5 0.07 
5 0.14   10 0.13 
10 0.20   30 0.35 
15 0.53   50 0.41 
25 0.83   100 0.64 
PBS-1086 
2 0.81 2 0.55 50 0 
5 2.33 5 1.01   
10 5.48 10 2.66   
20 9.23 20 3.21   
35 18.22 35 6.01   
β-estradiol 
2 0.75 2 0.98 2 0.67 
5 2.01 5 2.21 5 1.31 
10 5.03 10 4.51 10 2.23 
20 11.5 20 10.2 50 9.21 
35 14.0 35 12.1 100 18.9 





ethynylestradiol 5 2.01 5 2.21 5 3.21 
 
 
 III-1d III-1e HPCD 
 [Host] [Drug] [Host] [Drug] [Host] [Drug] 
17α - 
ethynylestradiol 
10 4.30 10 4.84 10 5.51 
20 9.03 20 8.32 20 12.1 
35 13.2 35 15.6 35 16.3 
Itraconazole 
2 0.09 2 0.06 100 0 
5 0.13 5 0.14   
10 0.32 10 0.20   
20 0.47 20 0.44   
30 0.51 35 0.57   
Aripriprzole 30 0 30 0 30 0 
Fenofibrate 35 0 35 0 100 0 
Docetaxel 35 0 35 0 100 0 
Voriconazole 
2 1.32 2 0.98 2 0.61 
4 2.21 4 1.77 4 0.88 
6 4.21 6 5.31 6 1.52 
8 6.38 8 6.44 8 1.77 
10 7.57 10 8.86 10 2.40 
Fulvestrant 30 0 30 0 100 0 
Ziprasidone 2 0.92 2 1.11 2 0.08 
 5 1.97 5 2.03 5 0.17 
 10 4.54 10 4.30 10 0.28 
 20 8.21 20 9.21 20 0.63 


































Figure S III-14. Phase solubility diagram of albendazole with different hosts in phosphate 
buffer (20 mM, pH 7.4, RT). 























Figure S III-15. Phase solubility diagram of taxol with different hosts in phosphate buffer 
































Figure S III-16. Phase solubility diagram of melphalan with different hosts in phosphate 
buffer (20 mM, pH 7.4, RT). 
























Figure S III-17. Phase solubility diagram of tamoxifen with different hosts in phosphate 





























Figure S III-18. Phase solubility diagram of cinnarizine with different hosts in phosphate 
buffer (20 mM, pH 7.4, RT). 































Figure S III-19. Phase solubility diagram of amiodarone with different hosts in phosphate 







































Figure S III-20. Phase solubility diagram of camptothecin with different hosts in phosphate 
buffer (20 mM, pH 7.4, RT). 
























Figure S III-21. Phase solubility diagram of PBS-1086 with different hosts in phosphate 






























Figure S III-22. Phase solubility diagram of itraconazole with different hosts in phosphate 
buffer (20 mM, pH 7.4, RT). 





































Figure S III-23. Phase solubility diagram of aripiprizole with different hosts in phosphate 




























Figure S III-24. Phase solubility diagram of fenofibrate with different hosts in phosphate 
buffer (20 mM, pH 7.4, RT). 




























Figure S III-25. Phase solubility diagram of docetaxel with different hosts in phosphate 
































Figure S III-26. Phase solubility diagram of ziprasidone with different hosts in phosphate 
buffer (20 mM, pH 7.4, RT). 































Figure S III-27. Phase solubility diagram of β - estradiol with different hosts in phosphate 






































Figure S III-28. Phase solubility diagram of 17α - ethynylestradiol with different hosts in 
phosphate buffer (20 mM, pH 7.4, RT). 
 






























Figure S III-29. Phase solubility diagram of voriconazole with different hosts in phosphate 






























Figure S III-30. Phase solubility diagram of fulvestrant with different hosts in phosphate 
buffer (20 mM, pH 7.4, RT). 




























Figure S III-31. Phase solubility diagram of indomethacin with different hosts in phosphate 


































Figure S III-32. Phase solubility diagram of tolfenamic acid with different hosts in 







Figure S III-33. 1H NMR recorded for pharmaceutical agent Aripiprazole with III-1a (10 












Figure S III-34. 1H NMR recorded for pharmaceutical agent PBS-1086 with III-1a (15 mM) 






Figure S III-35. 1H NMR recorded for pharmaceutical agent Docetaxel with III-1a (10 mM) 






Figure S III-36. 1H NMR recorded for pharmaceutical agent 17α-ethynylestradiol with III-







Figure S III-37. 1H NMR recorded for pharmaceutical agent β-estradiol with III-1a (10 mM) 






Figure S III-38. 1H NMR recorded for pharmaceutical agent camptothecin with III-1a (10 







Figure S III-39. 1H NMR recorded for pharmaceutical agent Indomethacin with III-1a (20 







Figure S III-40. 1H NMR recorded for pharmaceutical agent Tolfenamic acid with III-1a (10 







Figure S III-41. 1H NMR recorded for pharmaceutical agent Voriconazole with III-1a (10 







Figure S III-42. 1H NMR recorded for pharmaceutical agent ziprasidone with III-1a (10 













Figure S III-43. 1H NMR recorded for pharmaceutical agent PBS-1086 with III-1b (8 mM) 








Figure S III-44. 1H NMR recorded for pharmaceutical agent β-estradiol with III-1b (10 







Figure S III-45. 1H NMR recorded for pharmaceutical agent 17α-ethynylestradiol with III-







Figure S III-46. 1H NMR recorded for pharmaceutical agent Fenofibrate with III-1b (10 







Figure S III-47. 1H NMR recorded for pharmaceutical agent Aripiprazole with III-1b (10 







Figure S III-48. 1H NMR recorded for pharmaceutical agent Fulvestrant with III-1b (4 mM) 






Figure S III-49. 1H NMR recorded for pharmaceutical agent Voriconazole with III-1b (10 







Figure S III-50. 1H NMR recorded for pharmaceutical agent ziprasidone with III-1b (10 







Figure S III-51. 1H NMR recorded for pharmaceutical agent PBS-1086 with III-1c (10 mM) 






Figure S III-52. 1H NMR recorded for pharmaceutical agent Tolfenamic acid with III-1c (15 






Figure S III-53. 1H NMR recorded for pharmaceutical agent Amiodarone with III-1c (10 






Figure S III-54. 1H NMR recorded for pharmaceutical agent Tamoxifen with III-1c (10 






Figure S III-55. 1H NMR recorded for pharmaceutical agent Camptothecin with III-1c (10 






Figure S III-56. 1H NMR recorded for pharmaceutical agent Itraconazole with III-1c (10 






Figure S III-57. 1H NMR recorded for pharmaceutical agent albendazole with III-1c (10 






Figure S III-58. 1H NMR recorded for pharmaceutical agent β-estradiol with III-1c (10 mM) 






Figure S III-59. 1H NMR recorded for pharmaceutical agent 17α-ethynylestradiol with III-






Figure S III-60. 1H NMR recorded for pharmaceutical agent indomethacin with III-1c (35 






Figure S III-61. 1H NMR recorded for pharmaceutical agent Voriconazole with III-1c (10 







Figure S III-62. 1H NMR recorded for pharmaceutical agent Ziprasidone with III-1c (10 







Figure S III-63. 1H NMR recorded for pharmaceutical agent Albendazole with III-1d (10 







Figure S III-64. 1H NMR recorded for pharmaceutical agent PBS-1086 with III-1d (10 mM) 






Figure S III-65. 1H NMR recorded for pharmaceutical agent 17α-ethynylestradiol with III-







Figure S III-66. 1H NMR recorded for pharmaceutical agent β-estradiol with III-1d (10 







Figure S III-67. 1H NMR recorded for pharmaceutical agent Amiodarone with III-1d (10 











Figure S III-68. 1H NMR recorded for pharmaceutical agent Camptothecin with III-1d (30 







Figure S III-69. 1H NMR recorded for pharmaceutical agent Indomethacin with III-1d (10 







Figure S III-70. 1H NMR recorded for pharmaceutical agent Itraconazole with III-1d (10 







Figure S III-71. 1H NMR recorded for pharmaceutical agent Melphalan with III-1d (10 







Figure S III-72. 1H NMR recorded for pharmaceutical agent Tamoxifen with III-1d (10 







Figure S III-73. 1H NMR recorded for pharmaceutical agent tolfenamic acid with III-1d (10 







Figure S III-74. 1H NMR recorded for pharmaceutical agent Voriconazole with III-1d (10 







Figure S III-75. 1H NMR recorded for pharmaceutical agent ziprasidone with III-1d (10 







Figure S III-76. 1H NMR recorded for pharmaceutical agent Amiodarone with III-1e (10 







Figure S III-77. 1H NMR recorded for pharmaceutical agent 17α-ethynylestradiol with III-







Figure S III-78. 1H NMR recorded for pharmaceutical agent PBS-1086 with III-1e (10 mM) 






Figure S III-79. 1H NMR recorded for pharmaceutical agent β-estradiol with III-1e (10 mM) 






Figure S III-80. 1H NMR recorded for pharmaceutical agent camptothecin with III-1e (10 







Figure S III-81. 1H NMR recorded for pharmaceutical agent cinnarizine with III-1e (10 







Figure S III-82. 1H NMR recorded for pharmaceutical agent itraconazole with III-1e (10 







Figure S III-83. 1H NMR recorded for pharmaceutical agent Melphalan with III-1e (10 mM) 






Figure S III-84. 1H NMR recorded for pharmaceutical agent Voriconazole with III-1e (10 







Figure S III-85. 1H NMR recorded for pharmaceutical agent ziprasidone with III-1e (10 







Figure S III-86. 1H NMR recorded for pharmaceutical agent Albendazole with HP-β-CD (5 








Figure S III-87. 1H NMR recorded for pharmaceutical agent Amiodarone with HP-β-CD (10 







Figure S III-88. 1H NMR recorded for pharmaceutical agent 17α-ethynylestradiol with HP-







Figure S III-89. 1H NMR recorded for pharmaceutical agent β-estradiol with HP-β-CD (10 







Figure S III-90. 1H NMR recorded for pharmaceutical agent Cinnarizine with HP-β-CD (10 







Figure S III-91. 1H NMR recorded for pharmaceutical agent Indomethacin with HP-β-CD 







Figure S III-92. 1H NMR recorded for pharmaceutical agent Tamoxifen with HP-β-CD (10 







Figure S III-93. 1H NMR recorded for pharmaceutical agent Tolfenamic acid with HP-β-CD 







Figure S III-94. 1H NMR recorded for pharmaceutical agent Voriconazole with HP-β-CD 







Figure S III-95. 1H NMR recorded for pharmaceutical agent Ziprasidone with HP-β-CD (10 
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